CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | f-block element atom |
|
Accession: | CHEBI:33562
|
browse the term
|
Synonyms: | related_synonym: | f-block element; f-block elements |
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of AKT1 mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alb |
albumin |
decreases expression affects expression increases secretion |
EXP ISO |
ceric oxide results in decreased expression of ALB protein ceric oxide affects the expression of ALB mRNA ceric oxide results in increased secretion of ALB protein |
CTD |
PMID:22072870 PMID:23726862 PMID:29463257 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of AP3D1 mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 7:11,838,639...11,873,992
Ensembl chr 7:11,838,639...11,873,984
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
ceric oxide results in increased expression of APAF1 protein |
CTD |
PMID:24987704 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
ceric oxide results in increased expression of BAX protein |
CTD |
PMID:24987704 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
ceric oxide results in decreased expression of BCL2 protein |
CTD |
PMID:24987704 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
EXP |
ceric oxide results in increased expression of BIRC5 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression |
EXP |
ceric oxide results in decreased expression of BRCA1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
|
|
G |
Casp3 |
caspase 3 |
increases cleavage increases expression |
ISO |
ceric oxide results in increased cleavage of CASP3 protein ceric oxide results in increased expression of CASP3 protein |
CTD |
PMID:24987704 PMID:26028148 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
affects expression |
ISO |
ceric oxide analog affects the expression of CASP7 mRNA |
CTD |
PMID:22960666 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
ceric oxide results in increased expression of CASP9 protein |
CTD |
PMID:24987704 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
decreases activity affects expression multiple interactions |
ISO EXP |
ceric oxide results in decreased activity of CAT protein ceric oxide affects the expression of CAT protein Acetylcysteine inhibits the reaction [ceric oxide results in decreased activity of CAT protein] |
CTD |
PMID:20457660 PMID:23416263 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions increases expression |
ISO EXP |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in decreased expression of CCL11 mRNA; [Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CCL11 protein; ceric oxide promotes the reaction [Antigens, Dermatophagoides results in increased expression of CCL11 mRNA] ceric oxide results in increased expression of CCL11 mRNA |
CTD |
PMID:29463257 PMID:29792201 |
|
NCBI chr10:69,434,965...69,439,566
Ensembl chr10:69,434,941...69,439,575
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
multiple interactions increases expression |
ISO EXP |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CCL17 mRNA ceric oxide results in increased expression of CCL17 mRNA |
CTD |
PMID:29463257 PMID:29792201 |
|
NCBI chr19:10,619,220...10,620,671
Ensembl chr19:10,619,220...10,620,671
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression increases secretion |
ISO EXP |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in decreased expression of CCL2 mRNA ceric oxide results in increased expression of CCL2 mRNA ceric oxide results in increased secretion of CCL2 protein |
CTD |
PMID:29463257 PMID:29792201 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions affects expression |
ISO EXP |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CCL20 mRNA ceric oxide affects the expression of CCL20 mRNA |
CTD |
PMID:29463257 PMID:29792201 |
|
NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
increases expression |
EXP |
ceric oxide results in increased expression of CCL22 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
increases expression |
EXP |
ceric oxide results in increased expression of CCL24 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr12:24,131,529...24,152,626
Ensembl chr12:24,148,567...24,152,625
|
|
G |
Ccl26 |
C-C motif chemokine ligand 26 |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CCL26 mRNA |
CTD |
PMID:29792201 |
|
NCBI chr12:24,157,182...24,161,870
Ensembl chr12:24,158,766...24,161,869
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
EXP |
ceric oxide results in increased expression of CCL3 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression |
EXP |
ceric oxide results in increased expression of CCL4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
EXP |
ceric oxide results in increased expression of CCL7 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
EXP |
ceric oxide results in increased expression of CCR2 mRNA |
CTD |
PMID:29463257 |
|
|
|
G |
Cd177 |
CD177 molecule |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CD177 mRNA |
CTD |
PMID:29792201 |
|
NCBI chr 1:82,964,683...82,987,306
Ensembl chr 1:82,964,683...82,987,253
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression |
EXP |
ceric oxide results in decreased expression of CD40LG mRNA |
CTD |
PMID:29463257 |
|
NCBI chr X:159,703,703...159,714,886
Ensembl chr X:159,703,578...159,716,562
|
|
G |
Cd63 |
Cd63 molecule |
increases expression |
ISO |
ceric oxide results in increased expression of CD63 protein |
CTD |
PMID:23726862 |
|
NCBI chr 7:3,320,250...3,335,583
Ensembl chr 7:3,320,103...3,335,582
|
|
G |
Clca1 |
chloride channel accessory 1 |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CLCA1 mRNA [Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CLCA1 mRNA; ceric oxide promotes the reaction [Antigens, Dermatophagoides results in increased expression of CLCA1 protein] |
CTD |
PMID:29792201 |
|
NCBI chr 2:250,897,980...250,923,711
Ensembl chr 2:250,897,969...250,923,744
|
|
G |
Clec10a |
C-type lectin domain containing 10A |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CLEC10A mRNA |
CTD |
PMID:29792201 |
|
NCBI chr10:56,764,927...56,769,447
Ensembl chr10:56,764,927...56,769,457
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases expression |
EXP |
ceric oxide results in increased expression of CX3CL1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr19:10,644,267...10,654,861
Ensembl chr19:10,644,244...10,653,800
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
affects expression |
EXP |
ceric oxide affects the expression of CX3CR1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:128,740,756...128,754,514
Ensembl chr 8:128,740,756...128,754,514
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
ceric oxide inhibits the reaction [Antigens, Dermatophagoides results in increased expression of CXCL10 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
EXP |
ceric oxide results in decreased expression of CXCL12 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
affects expression |
EXP |
ceric oxide affects the expression of CXCL9 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
increases expression |
EXP |
ceric oxide results in increased expression of CXCR2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 9:81,427,275...81,435,065
Ensembl chr 9:81,427,730...81,434,102
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
increases expression |
EXP |
ceric oxide results in increased expression of CXCR3 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr X:71,614,346...71,616,997
Ensembl chr X:71,614,346...71,616,997
|
|
G |
Cxcr5 |
C-X-C motif chemokine receptor 5 |
decreases expression |
EXP |
ceric oxide results in decreased expression of CXCR5 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:48,835,688...48,852,032
Ensembl chr 8:48,836,957...48,850,671
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:29792201 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
affects expression |
EXP |
ceric oxide affects the expression of CYP1B1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Dbnl |
drebrin-like |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of DBNL mRNA |
CTD |
PMID:24821434 |
|
NCBI chr14:86,029,335...86,044,364
Ensembl chr14:86,029,335...86,044,364
|
|
G |
Epx |
eosinophil peroxidase |
decreases expression |
EXP |
ceric oxide results in decreased expression of EPX mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:75,160,690...75,171,774
Ensembl chr10:75,160,690...75,171,774
|
|
G |
Exo1 |
exonuclease 1 |
affects expression |
EXP |
ceric oxide affects the expression of EXO1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr13:93,936,989...93,962,749
Ensembl chr13:93,939,022...93,960,342
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
EXP |
ceric oxide results in increased expression of FABP4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression |
EXP |
ceric oxide results in decreased expression of GCLC mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
decreases expression |
EXP |
ceric oxide results in decreased expression of GCLM mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
decreases expression |
EXP |
ceric oxide results in decreased expression of GPX2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
decreases expression |
EXP |
ceric oxide results in decreased expression of HBA1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:15,589,364...15,590,207
Ensembl chr10:15,589,364...15,590,220
|
|
G |
Hfe |
homeostatic iron regulator |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of HFE mRNA |
CTD |
PMID:24821434 |
|
NCBI chr17:43,661,276...43,669,327
Ensembl chr17:43,661,222...43,669,985
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression multiple interactions decreases expression increases expression |
ISO |
ceric oxide analog affects the expression of HMOX1 mRNA ceric oxide inhibits the reaction [potassium bromate results in increased expression of HMOX1 mRNA] ceric oxide results in decreased expression of HMOX1 mRNA ceric oxide results in increased expression of HMOX1 protein |
CTD |
PMID:19429248 PMID:22960666 PMID:25618551 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of ID2 mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 6:44,360,077...44,361,908
Ensembl chr 6:44,348,501...44,363,915
|
|
G |
Ifit1 |
interferon-induced protein with tetratricopeptide repeats 1 |
multiple interactions |
ISO |
ceric oxide inhibits the reaction [Antigens, Dermatophagoides results in increased expression of IFIT1 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr 1:252,944,105...252,946,170
Ensembl chr 1:252,944,103...252,946,170
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
ceric oxide inhibits the reaction [Antigens, Dermatophagoides results in increased expression of IL13 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
EXP |
ceric oxide results in increased expression of IL1A mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
ceric oxide results in increased expression of IL1B mRNA; ceric oxide results in increased expression of IL1B protein |
CTD |
PMID:21624445 PMID:29463257 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression |
EXP |
ceric oxide results in increased expression of IL1RN mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Il2rb |
interleukin 2 receptor subunit beta |
decreases expression |
EXP |
ceric oxide results in decreased expression of IL2RB mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 7:119,701,338...119,716,238
Ensembl chr 7:119,701,251...119,716,238
|
|
G |
Il2rg |
interleukin 2 receptor subunit gamma |
increases expression |
EXP |
ceric oxide results in increased expression of IL2RG mRNA |
CTD |
PMID:29463257 |
|
NCBI chr X:71,165,378...71,169,078
Ensembl chr X:71,162,585...71,169,865
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
ceric oxide promotes the reaction [Antigens, Dermatophagoides results in increased expression of IL4 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
EXP ISO |
ceric oxide results in increased expression of IL6 protein [Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of IL6 mRNA |
CTD |
PMID:21624445 PMID:29792201 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Irf7 |
interferon regulatory factor 7 |
multiple interactions |
ISO |
ceric oxide inhibits the reaction [Antigens, Dermatophagoides results in increased expression of IRF7 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr 1:214,249,388...214,252,909
Ensembl chr 1:214,248,837...214,252,456
|
|
G |
Kif13b |
kinesin family member 13B |
increases expression |
ISO |
ceric oxide analog results in increased expression of KIF13B mRNA |
CTD |
PMID:24821434 |
|
NCBI chr15:48,030,837...48,192,932
Ensembl chr15:48,030,973...48,189,951
|
|
G |
Kitlg |
KIT ligand |
increases expression |
ISO |
ceric oxide analog results in increased expression of KITLG mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
|
|
G |
Lig4 |
DNA ligase 4 |
affects expression |
EXP |
ceric oxide affects the expression of LIG4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr16:85,331,771...85,339,496
Ensembl chr16:85,331,866...85,337,769
|
|
G |
Lpo |
lactoperoxidase |
increases expression |
EXP |
ceric oxide results in increased expression of LPO mRNA; ceric oxide results in increased expression of LPO protein |
CTD |
PMID:29463257 |
|
NCBI chr10:75,100,385...75,120,247
Ensembl chr10:75,100,385...75,120,247
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
ceric oxide results in increased phosphorylation of MAPK1 protein Acetylcysteine inhibits the reaction [ceric oxide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23416263 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [ceric oxide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23416263 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions increases expression |
ISO EXP |
ceric oxide promotes the reaction [Antigens, Dermatophagoides results in increased expression of MMP12 mRNA] ceric oxide results in increased expression of MMP12 mRNA; ceric oxide results in increased expression of MMP12 protein |
CTD |
PMID:29463257 PMID:29792201 |
|
NCBI chr 8:5,594,717...5,616,494
Ensembl chr 8:5,606,592...5,616,493
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity increases secretion |
ISO |
ceric oxide results in increased activity of MMP9 protein ceric oxide results in increased secretion of MMP9 protein |
CTD |
PMID:23726862 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
increases secretion increases expression |
ISO EXP |
ceric oxide results in increased secretion of MPO protein ceric oxide results in increased expression of MPO mRNA |
CTD |
PMID:23726862 PMID:29463257 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Msh5 |
mutS homolog 5 |
increases expression |
EXP |
ceric oxide results in increased expression of MSH5 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr20:5,020,690...5,037,125
Ensembl chr20:5,020,667...5,037,088
|
|
G |
Muc1 |
mucin 1, cell surface associated |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of MUC1 mRNA |
CTD |
PMID:29792201 |
|
NCBI chr 2:188,543,137...188,547,874
Ensembl chr 2:188,543,137...188,547,874
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of MUC5AC mRNA |
CTD |
PMID:29792201 |
|
NCBI chr 1:214,725,482...214,756,653
|
|
G |
Mutyh |
mutY DNA glycosylase |
decreases expression |
EXP |
ceric oxide results in decreased expression of MUTYH mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 5:135,663,328...135,675,348
Ensembl chr 5:135,663,371...135,675,344
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
increases expression decreases expression |
EXP |
ceric oxide results in increased expression of NCF2 mRNA ceric oxide results in decreased expression of NCF2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr13:70,226,441...70,259,019
Ensembl chr13:70,226,647...70,257,576
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization |
ISO |
ceric oxide affects the localization of NFE2L2 protein |
CTD |
PMID:19429248 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Ngb |
neuroglobin |
decreases expression |
EXP |
ceric oxide results in decreased expression of NGB mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 6:111,126,259...111,131,699
Ensembl chr 6:111,126,261...111,132,320
|
|
G |
Noxo1 |
NADPH oxidase organizer 1 |
increases expression |
EXP |
ceric oxide results in increased expression of NOXO1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:14,062,331...14,066,918
Ensembl chr10:14,062,331...14,066,918
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of NQO1 mRNA |
CTD |
PMID:29792201 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Opcml |
opioid binding protein/cell adhesion molecule-like |
increases expression |
EXP |
ceric oxide results in increased expression of OPCML mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:28,842,202...29,967,300
Ensembl chr 8:29,453,643...29,962,825
|
|
G |
Osm |
oncostatin M |
affects expression |
EXP |
ceric oxide affects the expression of OSM mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:84,457,487...84,469,426
Ensembl chr14:84,465,515...84,470,409
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
EXP |
ceric oxide results in increased expression of PF4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:18,848,549...18,849,258
Ensembl chr14:18,848,549...18,849,258
|
|
G |
Scd |
stearoyl-CoA desaturase |
affects expression |
EXP |
ceric oxide affects the expression of SCD1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Sectm1b |
secreted and transmembrane 1B |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of SECTM1 mRNA |
CTD |
PMID:24821434 |
|
NCBI chr10:110,251,363...110,260,577
Ensembl chr10:110,251,363...110,259,985
|
|
G |
Slc26a4 |
solute carrier family 26 member 4 |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of SLC26A4 mRNA [Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of SLC26A4 mRNA; ceric oxide promotes the reaction [Antigens, Dermatophagoides results in increased expression of SLC26A4 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr 6:50,809,103...50,848,443
Ensembl chr 6:50,808,923...50,846,965
|
|
G |
Smug1 |
single-strand-selective monofunctional uracil-DNA glycosylase 1 |
increases expression |
EXP |
ceric oxide results in increased expression of SMUG1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 7:144,774,155...144,788,333
Ensembl chr 7:144,774,160...144,778,656
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
ceric oxide inhibits the reaction [potassium bromate results in increased expression of SOD2 mRNA] ceric oxide results in increased expression of SOD2 mRNA |
CTD |
PMID:25618551 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
EXP |
ceric oxide results in decreased expression of SPP1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Tafazzin |
tafazzin, phospholipid-lysophospholipid transacylase |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of TAFAZZIN mRNA |
CTD |
PMID:24821434 |
|
NCBI chr X:156,421,006...156,429,461
Ensembl chr X:156,421,009...156,428,593
|
|
G |
Tirap |
TIR domain containing adaptor protein |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of TIRAP mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 8:36,382,029...36,399,625
Ensembl chr 8:36,385,353...36,388,224
|
|
G |
Tlr6 |
toll-like receptor 6 |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of TLR6 mRNA |
CTD |
PMID:24821434 |
|
NCBI chr14:45,024,351...45,041,188
Ensembl chr14:45,024,351...45,046,446
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP ISO |
ceric oxide results in increased expression of TNF protein |
CTD |
PMID:21624445 PMID:27693598 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf4 |
TNF superfamily member 4 |
affects expression |
EXP |
ceric oxide affects the expression of TNFSF4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr13:79,269,973...79,293,775
Ensembl chr13:79,269,973...79,293,778
|
|
G |
Tollip |
toll interacting protein |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of TOLLIP mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 1:214,823,993...214,844,861
Ensembl chr 1:214,823,978...214,844,858
|
|
G |
Tp53 |
tumor protein p53 |
increases phosphorylation |
ISO |
ceric oxide results in increased phosphorylation of TP53 protein |
CTD |
PMID:24987704 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of TSLP mRNA |
CTD |
PMID:29792201 |
|
NCBI chr18:25,613,601...25,618,066
Ensembl chr18:25,613,831...25,617,361
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
EXP |
ceric oxide results in decreased expression of TXNIP mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 2:198,683,168...198,686,971
Ensembl chr 2:198,683,159...198,686,974
|
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Cerium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:82,129,071...82,197,828
Ensembl chr10:82,129,506...82,197,848
|
|
|
G |
Abhd14b |
abhydrolase domain containing 14b |
increases expression |
ISO |
cerous chloride results in increased expression of ABHD14B mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:115,149,638...115,154,556
Ensembl chr 8:115,150,514...115,154,550
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
increases expression |
ISO |
cerous chloride results in increased expression of ACAA1A mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:128,027,880...128,036,471
Ensembl chr 8:128,027,958...128,036,236
|
|
G |
Adcy8 |
adenylate cyclase 8 |
decreases expression |
ISO |
cerous chloride results in decreased expression of ADCY8 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:105,353,883...105,593,372
Ensembl chr 7:105,353,913...105,592,804
|
|
G |
Adgrb3 |
adhesion G protein-coupled receptor B3 |
increases expression |
ISO |
cerous chloride results in increased expression of ADGRB3 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 9:31,280,623...32,022,535
Ensembl chr 9:31,281,316...32,019,205
|
|
G |
Adora2b |
adenosine A2B receptor |
decreases expression |
ISO |
cerous chloride results in decreased expression of ADORA2B mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:48,569,563...48,586,366
Ensembl chr10:48,569,555...48,586,365
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
increases expression |
ISO |
cerous chloride results in increased expression of AGO2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:114,339,607...114,377,277
Ensembl chr 7:114,339,434...114,380,613
|
|
G |
Agpat1 |
1-acylglycerol-3-phosphate O-acyltransferase 1 |
decreases expression |
ISO |
cerous chloride results in decreased expression of AGPAT1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr20:4,369,399...4,378,272
Ensembl chr20:4,369,178...4,378,269
|
|
G |
Akap17a |
A-kinase anchoring protein 17A |
increases expression |
ISO |
cerous chloride results in increased expression of AKAP17B mRNA |
CTD |
PMID:23573234 |
|
NCBI chr12:18,527,116...18,531,780
Ensembl chr12:18,526,422...18,531,161
|
|
G |
Alb |
albumin |
affects expression |
ISO |
cerous chloride affects the expression of ALB mRNA |
CTD |
PMID:23139204 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of ALOX12 mRNA [cerous chloride co-treated with lanthanum chloride] results in decreased expression of ALOX12 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:56,851,734...56,864,049
Ensembl chr10:56,851,734...56,864,005
|
|
G |
Anp32e |
acidic nuclear phosphoprotein 32 family member E |
increases expression |
ISO |
cerous chloride results in increased expression of ANP32E mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:198,040,573...198,057,005
Ensembl chr 2:198,040,536...198,057,003
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of AOX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
|
|
G |
Apoa2 |
apolipoprotein A2 |
increases expression |
ISO |
cerous chloride results in increased expression of APOA2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr13:89,596,872...89,598,805
Ensembl chr13:89,597,138...89,598,802
|
|
G |
Apoa4 |
apolipoprotein A4 |
affects expression |
ISO |
cerous chloride affects the expression of APOA4 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
|
|
G |
Apoe |
apolipoprotein E |
affects expression multiple interactions |
ISO |
cerous chloride affects the expression of APOE mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of APOE mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
decreases expression |
ISO |
cerous chloride results in decreased expression of ARC mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:115,907,097...115,911,059
Ensembl chr 7:115,907,097...115,910,541
|
|
G |
Arhgef15 |
Rho guanine nucleotide exchange factor 15 |
increases expression |
ISO |
cerous chloride results in increased expression of ARHGEF15 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:55,532,097...55,545,675
Ensembl chr10:55,532,077...55,544,429
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
increases expression |
ISO |
cerous chloride results in increased expression of LBCL1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:187,964,100...188,022,847
Ensembl chr 2:187,977,008...188,021,377
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
ISO |
cerous chloride results in increased expression of B2M mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
|
|
G |
Bcl9 |
BCL9, transcription coactivator |
increases expression |
ISO |
cerous chloride results in increased expression of BCL9 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:199,334,644...199,420,083
Ensembl chr 2:199,334,664...199,354,793
|
|
G |
Bclaf1 |
BCL2-associated transcription factor 1 |
increases expression |
ISO |
cerous chloride results in increased expression of BCLAF1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:15,799,753...15,828,838
Ensembl chr 1:15,782,477...15,860,624
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
ISO |
cerous chloride results in increased expression of CALM2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 6:11,067,675...11,080,078
Ensembl chr15:65,506,874...65,507,968
|
|
G |
Camp |
cathelicidin antimicrobial peptide |
increases expression |
ISO |
cerous chloride results in increased expression of CAMP mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:117,930,557...117,932,371
Ensembl chr 8:117,930,546...117,932,518
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of CAT mRNA cerous chloride results in decreased expression of CAT mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression multiple interactions |
ISO |
cerous chloride results in increased expression of CCL5 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of CCL5 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccnt2 |
cyclin T2 |
increases expression |
ISO |
cerous chloride results in increased expression of CCNT2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr13:44,475,959...44,516,892
Ensembl chr13:44,475,970...44,515,739
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] affects the expression of CCS mRNA cerous chloride results in decreased expression of CCS mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:220,075,251...220,096,319
Ensembl chr 1:220,075,247...220,096,404
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
increases expression |
ISO |
cerous chloride results in increased expression of CDC37 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:22,160,922...22,173,797
Ensembl chr 8:22,154,067...22,173,804
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO |
cerous chloride results in decreased expression of CDKN1A mRNA |
CTD |
PMID:23139204 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
ISO |
cerous chloride results in increased expression of CEL mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Celf2 |
CUGBP, Elav-like family member 2 |
increases expression |
ISO |
cerous chloride results in increased expression of CELF2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr17:75,259,269...75,660,154
Ensembl chr17:75,352,389...75,654,951
|
|
G |
Cep63 |
centrosomal protein 63 |
decreases expression |
ISO |
cerous chloride results in decreased expression of CEP63 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:111,063,988...111,116,014
Ensembl chr 8:111,064,049...111,116,014
|
|
G |
Cfd |
complement factor D |
affects expression |
ISO |
cerous chloride affects the expression of CFD mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
|
|
G |
Cfp |
complement factor properdin |
increases expression |
ISO |
cerous chloride results in increased expression of CFP mRNA |
CTD |
PMID:23573234 |
|
NCBI chr X:1,311,121...1,316,683
Ensembl chr X:1,311,121...1,316,682
|
|
G |
Chmp5 |
charged multivesicular body protein 5 |
decreases expression |
ISO |
cerous chloride results in decreased expression of CHMP5 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 5:57,267,312...57,284,455
Ensembl chr 5:57,267,312...57,284,448
|
|
G |
Chrd |
chordin |
increases expression |
ISO |
cerous chloride results in increased expression of CHRD mRNA |
CTD |
PMID:23573234 |
|
NCBI chr11:83,858,503...83,867,543
Ensembl chr11:83,858,503...83,867,203
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression |
ISO |
cerous chloride results in increased expression of CHUK mRNA; cerous chloride results in increased expression of CHUK protein |
CTD |
PMID:21656643 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Clasp2 |
cytoplasmic linker associated protein 2 |
increases expression |
ISO |
cerous chloride results in increased expression of CLASP2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:122,003,719...122,185,495
Ensembl chr 8:122,003,916...122,185,495
|
|
G |
Cnot3 |
CCR4-NOT transcription complex, subunit 3 |
increases expression |
ISO |
cerous chloride results in increased expression of CNOT3 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:64,130,823...64,147,066
Ensembl chr 1:64,130,908...64,147,251
|
|
G |
Cspg5 |
chondroitin sulfate proteoglycan 5 |
increases expression |
ISO |
cerous chloride results in increased expression of CSPG5 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:118,333,695...118,348,040
Ensembl chr 8:118,333,706...118,347,582
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
increases expression |
ISO |
cerous chloride results in increased expression of AXUD1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:128,659,883...128,673,339
Ensembl chr 8:128,659,868...128,672,284
|
|
G |
Cttnbp2 |
cortactin binding protein 2 |
increases expression |
ISO |
cerous chloride results in increased expression of CTTNBP2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 4:42,932,897...43,096,454
Ensembl chr 4:42,932,903...43,096,399
|
|
G |
Cul1 |
cullin 1 |
increases expression |
ISO |
cerous chloride results in increased expression of CUL1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 4:77,211,814...77,283,369
Ensembl chr 4:77,211,692...77,280,250
|
|
G |
Cygb |
cytoglobin |
affects expression multiple interactions |
ISO |
cerous chloride affects the expression of CYGB mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of CYGB mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:105,618,325...105,628,091
Ensembl chr10:105,618,326...105,628,091
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
cerous chloride results in increased expression of CYP1A1 |
CTD |
PMID:23712967 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
increases expression |
ISO |
cerous chloride results in increased expression of CYP46A1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 6:132,242,328...132,273,788
Ensembl chr 6:132,242,328...132,273,787
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
affects expression |
ISO |
cerous chloride affects the expression of CYP51 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 4:27,175,564...27,194,018
Ensembl chr 4:27,175,243...27,194,018
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression |
ISO |
cerous chloride results in increased expression of CYP7B1 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
affects expression |
ISO |
cerous chloride affects the expression of CYP8B1 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 8:130,548,418...130,550,388
Ensembl chr 8:130,548,418...130,550,388
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
increases expression |
ISO |
cerous chloride results in increased expression of DCLK1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:144,646,255...144,939,389
Ensembl chr 2:144,646,308...144,936,927
|
|
G |
Dgkg |
diacylglycerol kinase, gamma |
increases expression |
ISO |
cerous chloride results in increased expression of DGKG mRNA |
CTD |
PMID:23573234 |
|
NCBI chr11:81,971,585...82,165,111
Ensembl chr11:81,972,219...82,163,165
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
decreases expression |
ISO |
cerous chloride results in decreased expression of DHCR24 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 5:126,164,708...126,188,926
Ensembl chr 5:126,164,674...126,191,206
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
affects expression |
ISO |
cerous chloride affects the expression of DHCR7 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 1:217,018,916...217,034,890
Ensembl chr 1:217,018,916...217,034,904
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
increases expression |
ISO |
cerous chloride results in increased expression of DLST mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 6:108,936,534...108,961,322
Ensembl chr 6:108,936,664...108,959,803
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
increases expression |
ISO |
cerous chloride results in increased expression of DNAJC7 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:88,498,271...88,533,730
Ensembl chr10:88,498,238...88,533,829
|
|
G |
Dock10 |
dedicator of cytokinesis 10 |
increases expression |
ISO |
cerous chloride results in increased expression of DOCK10 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 9:86,424,638...86,571,854 NCBI chr 9:86,312,470...86,423,054
Ensembl chr 9:86,312,501...86,571,870
|
|
G |
Dot1l |
DOT1 like histone lysine methyltransferase |
increases expression |
ISO |
cerous chloride results in increased expression of DOT1L mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:11,786,105...11,824,742
Ensembl chr 7:11,786,105...11,824,742
|
|
G |
Dpp8 |
dipeptidylpeptidase 8 |
increases expression |
ISO |
cerous chloride results in increased expression of DPP8 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:70,521,782...70,576,180
Ensembl chr 8:70,522,092...70,573,424
|
|
G |
Duox1 |
dual oxidase 1 |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of DUOX1 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of DUOX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:114,251,794...114,286,827
Ensembl chr 3:114,253,637...114,286,802
|
|
G |
Duox2 |
dual oxidase 2 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of DUOX2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:114,218,187...114,237,808
Ensembl chr 3:114,218,193...114,235,933
|
|
G |
Dus1l |
dihydrouridine synthase 1-like |
decreases expression |
ISO |
cerous chloride results in decreased expression of DUS1L mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:109,972,018...109,979,113
Ensembl chr10:109,972,037...109,979,712
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions affects expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of DUSP1 mRNA cerous chloride affects the expression of DUSP1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
affects expression |
ISO |
cerous chloride affects the expression of EBP mRNA |
CTD |
PMID:23139204 |
|
NCBI chr X:15,049,394...15,055,782
Ensembl chr X:15,049,462...15,055,781
|
|
G |
Eef1akmt1 |
EEF1A lysine methyltransferase 1 |
decreases expression |
ISO |
cerous chloride results in decreased expression of EEF1AKMT1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr15:37,813,115...37,830,932
Ensembl chr15:37,813,115...37,831,031
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of EGR2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
affects expression |
ISO |
cerous chloride affects the expression of EHHADH mRNA |
CTD |
PMID:23139204 |
|
NCBI chr11:82,945,104...82,978,364
Ensembl chr11:82,945,104...82,978,364
|
|
G |
Eif1b |
eukaryotic translation initiation factor 1B |
increases expression |
ISO |
cerous chloride results in increased expression of EIF1B mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:129,158,112...129,160,726
Ensembl chr 8:129,158,103...129,160,757
|
|
G |
Elfn2 |
extracellular leucine-rich repeat and fibronectin type III domain containing 2 |
increases expression |
ISO |
cerous chloride results in increased expression of ELFN2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:119,889,786...119,897,038
Ensembl chr 7:119,894,066...119,896,925
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
affects expression multiple interactions |
ISO |
cerous chloride affects the expression of EPHX2 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of EPHX2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Epx |
eosinophil peroxidase |
decreases expression |
ISO |
cerous chloride results in decreased expression of EPX mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:75,160,690...75,171,774
Ensembl chr10:75,160,690...75,171,774
|
|
G |
Fcrl2 |
Fc receptor-like 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of FCRLS mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:186,594,442...186,605,115
Ensembl chr 2:186,595,051...186,606,172
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
cerous chloride results in decreased expression of FOS mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxk2 |
forkhead box K2 |
increases expression |
ISO |
cerous chloride results in increased expression of FOXK2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:110,468,905...110,518,854
Ensembl chr10:110,469,290...110,518,848
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of FOXM1 mRNA cerous chloride results in decreased expression of FOXM1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 4:161,685,236...161,697,633
Ensembl chr 4:161,685,258...161,696,305
|
|
G |
Fpr2 |
formyl peptide receptor 2 |
increases expression |
ISO |
cerous chloride results in increased expression of FPR2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:59,800,558...59,809,507
Ensembl chr 1:59,800,984...59,802,401
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
cerous chloride results in increased expression of FTH1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Fus |
FUS RNA binding protein |
increases expression |
ISO |
cerous chloride results in increased expression of FUS mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:199,412,805...199,426,705
Ensembl chr 1:199,412,834...199,426,702
|
|
G |
Fxr2 |
FMR1 autosomal homolog 2 |
increases expression |
ISO |
cerous chloride results in increased expression of FXR2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:56,237,814...56,257,877
Ensembl chr10:56,237,755...56,257,890
|
|
G |
Fyco1 |
FYVE and coiled-coil domain autophagy adaptor 1 |
increases expression |
ISO |
cerous chloride results in increased expression of FYCO1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:132,844,042...132,910,905
Ensembl chr 8:132,844,043...132,911,193
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of GAPDH mRNA [cerous chloride co-treated with lanthanum chloride] results in decreased expression of GAPDH mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
cerous chloride results in increased expression of GCLC mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of GCLC mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
decreases expression |
ISO |
cerous chloride results in decreased expression of GCLM mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gnaq |
G protein subunit alpha q |
increases expression |
ISO |
cerous chloride results in increased expression of GNAQ mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:233,382,778...233,622,584
Ensembl chr 1:233,382,708...233,622,786
|
|
G |
Got1l1 |
glutamic-oxaloacetic transaminase 1-like 1 |
decreases expression |
ISO |
cerous chloride results in decreased expression of GOT1L1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr16:69,022,756...69,035,507
Ensembl chr16:69,022,784...69,028,179
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
affects expression |
ISO |
cerous chloride affects the expression of GPD2 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 3:43,223,892...43,359,069
Ensembl chr 3:43,255,567...43,359,074
|
|
G |
Gphn |
gephyrin |
increases expression |
ISO |
cerous chloride results in increased expression of GPHN mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 6:101,327,874...101,859,169
Ensembl chr 6:101,532,518...101,859,164
|
|
G |
Gpld1 |
glycosylphosphatidylinositol specific phospholipase D1 |
increases expression |
ISO |
cerous chloride results in increased expression of GPLD1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr17:42,085,027...42,131,344
Ensembl chr17:42,085,028...42,127,678
|
|
G |
Gpr153 |
G protein-coupled receptor 153 |
increases expression |
ISO |
cerous chloride results in increased expression of GPR153 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 5:169,450,275...169,463,878
Ensembl chr 5:169,452,493...169,462,713
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of GPX2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions affects expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of GPX3 mRNA cerous chloride affects the expression of GPX3 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:40,247,436...40,255,423
Ensembl chr10:40,247,436...40,255,422
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
affects expression |
ISO |
cerous chloride affects the expression of GPX4 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of GPX7 mRNA [cerous chloride co-treated with lanthanum chloride] results in decreased expression of GPX7 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 5:128,001,766...128,009,610
Ensembl chr 5:128,001,761...128,009,735
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
affects expression |
ISO |
cerous chloride affects the expression of GRB2 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr10:104,193,953...104,263,071
Ensembl chr10:104,193,955...104,263,071
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression |
ISO |
cerous chloride results in decreased expression of GSTP1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of GSTZ1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:111,176,798...111,187,246
Ensembl chr 6:111,176,798...111,187,244
|
|
G |
Gtf2i |
general transcription factor II I |
decreases expression |
ISO |
cerous chloride results in decreased expression of GTF2I mRNA |
CTD |
PMID:28954213 |
|
NCBI chr12:25,410,804...25,487,970
Ensembl chr12:25,411,207...25,488,156
|
|
G |
Hjurp |
Holliday junction recognition protein |
increases expression |
ISO |
cerous chloride results in increased expression of HJURP mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 9:95,347,739...95,362,228
Ensembl chr 9:95,349,086...95,362,014
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions affects expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of HMOX1 mRNA cerous chloride affects the expression of HMOX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression |
ISO |
cerous chloride results in decreased expression of HSPA1A mRNA |
CTD |
PMID:28954213 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
decreases expression |
ISO |
cerous chloride results in decreased expression of HSPE1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 9:61,691,246...61,724,948
Ensembl chr 9:61,692,154...61,694,599
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
cerous chloride results in increased expression of IFNG |
CTD |
PMID:23712967 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
increases expression |
ISO |
cerous chloride results in increased expression of IKBKB mRNA; cerous chloride results in increased expression of IKBKB protein |
CTD |
PMID:21656643 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
cerous chloride results in increased expression of IL10 |
CTD |
PMID:23712967 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
cerous chloride results in increased expression of IL18 |
CTD |
PMID:23712967 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
cerous chloride results in increased expression of IL1B |
CTD |
PMID:23712967 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
decreases expression increases expression |
ISO |
cerous chloride results in decreased expression of IL2 mRNA; cerous chloride results in decreased expression of IL2 protein cerous chloride results in increased expression of IL2 |
CTD |
PMID:21656643 PMID:23712967 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il4 |
interleukin 4 |
increases expression |
ISO |
cerous chloride results in increased expression of IL4 |
CTD |
PMID:23712967 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
IL6 mutant form inhibits the reaction [cerous chloride results in increased expression of SAA protein] cerous chloride results in increased expression of IL6; cerous chloride results in increased expression of IL6 protein |
CTD |
PMID:16204935 PMID:23712967 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Islr2 |
immunoglobulin superfamily containing leucine-rich repeat 2 |
increases expression |
ISO |
cerous chloride results in increased expression of ISLR2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:62,983,333...62,991,401
Ensembl chr 8:62,984,552...62,987,182
|
|
G |
Itfg1 |
integrin alpha FG-GAP repeat containing 1 |
increases expression |
ISO |
cerous chloride results in increased expression of ITFG1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr19:22,281,906...22,403,548
Ensembl chr19:22,281,906...22,403,542
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects expression |
ISO |
cerous chloride affects the expression of JUN mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kat7 |
lysine acetyltransferase 7 |
decreases expression |
ISO |
cerous chloride results in decreased expression of MYST2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:83,095,067...83,128,342
Ensembl chr10:83,095,068...83,128,297
|
|
G |
Kcna3 |
potassium voltage-gated channel subfamily A member 3 |
increases expression |
ISO |
cerous chloride results in increased expression of KCNA3 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:209,766,767...209,768,344
Ensembl chr 2:209,766,512...209,769,711
|
|
G |
Kcnj16 |
potassium inwardly-rectifying channel, subfamily J, member 16 |
increases expression |
ISO |
cerous chloride results in increased expression of KCNJ16 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:99,330,894...99,391,551
Ensembl chr10:99,388,130...99,389,898
|
|
G |
Kcnj4 |
potassium inwardly-rectifying channel, subfamily J, member 4 |
increases expression |
ISO |
cerous chloride results in increased expression of KCNJ4 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:120,717,378...120,744,602
Ensembl chr 7:120,717,375...120,744,602
|
|
G |
Kcnq5 |
potassium voltage-gated channel subfamily Q member 5 |
increases expression |
ISO |
cerous chloride results in increased expression of KCNQ5 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 9:27,565,869...28,141,114
Ensembl chr 9:27,562,959...27,761,733
|
|
G |
Klk6 |
kallikrein related-peptidase 6 |
decreases expression |
ISO |
cerous chloride results in decreased expression of KLK6 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:99,762,195...99,769,486
Ensembl chr 1:99,762,253...99,769,488
|
|
G |
Krt12 |
keratin 12 |
increases expression |
ISO |
cerous chloride results in increased expression of KRT12 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:87,328,547...87,336,710
Ensembl chr10:87,328,549...87,335,823
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
cerous chloride results in increased expression of LCN2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Lmnb2 |
lamin B2 |
increases expression |
ISO |
cerous chloride results in increased expression of LMNB2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:11,657,870...11,676,936
Ensembl chr 7:11,660,934...11,675,472
|
|
G |
Lpo |
lactoperoxidase |
multiple interactions increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of LPO mRNA cerous chloride results in increased expression of LPO mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:75,100,385...75,120,247
Ensembl chr10:75,100,385...75,120,247
|
|
G |
Ltf |
lactotransferrin |
increases expression |
ISO |
cerous chloride results in increased expression of LTF mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:119,290,416...119,313,261
Ensembl chr 8:119,290,416...119,313,261
|
|
G |
Mal |
mal, T-cell differentiation protein |
decreases expression |
ISO |
cerous chloride results in decreased expression of MAL mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 3:120,209,647...120,233,655
Ensembl chr 3:120,209,647...120,233,655
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
increases expression |
ISO |
cerous chloride results in increased expression of MAP4K4 mRNA; cerous chloride results in increased expression of MAP4K4 protein |
CTD |
PMID:21656643 |
|
NCBI chr 9:46,657,444...46,782,545
Ensembl chr 9:46,657,575...46,782,545
|
|
G |
Mat1a |
methionine adenosyltransferase 1A |
increases expression |
ISO |
cerous chloride results in increased expression of MAT1A mRNA |
CTD |
PMID:23573234 |
|
NCBI chr16:18,690,649...18,709,135
Ensembl chr16:18,690,246...18,709,133
|
|
G |
Mb |
myoglobin |
increases expression multiple interactions |
ISO |
cerous chloride results in increased expression of MB mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of MB mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 7:118,101,633...118,108,864
Ensembl chr 7:118,101,634...118,108,864
|
|
G |
Mbl2 |
mannose binding lectin 2 |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of MBL2 mRNA [cerous chloride co-treated with lanthanum chloride] results in decreased expression of MBL2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:248,435,069...248,442,669
Ensembl chr 1:248,723,397...248,729,962
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases expression |
ISO |
cerous chloride results in increased expression of MIF |
CTD |
PMID:23712967 |
|
NCBI chr20:13,715,219...13,732,980
Ensembl chr20:13,732,198...13,732,859
|
|
G |
Mpo |
myeloperoxidase |
affects expression |
ISO |
cerous chloride affects the expression of MPO mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mpv17 |
mitochondrial inner membrane protein MPV17 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of MPV17 mRNA cerous chloride results in decreased expression of MPV17 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:26,585,713...26,600,265
Ensembl chr 6:26,587,443...26,599,511
|
|
G |
Msra |
methionine sulfoxide reductase A |
decreases expression |
ISO |
cerous chloride results in decreased expression of MSRA mRNA |
CTD |
PMID:28954213 |
|
NCBI chr15:47,488,333...47,800,662
Ensembl chr15:47,488,894...47,800,024
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions |
ISO |
cerous chloride results in increased expression of MT1 protein cerous chloride promotes the reaction [Zinc binds to MT1 protein] |
CTD |
PMID:15964310 PMID:16204935 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions decreases expression increases expression |
ISO |
cerous chloride promotes the reaction [Zinc binds to MT2 protein] cerous chloride results in decreased expression of MT2 mRNA cerous chloride results in increased expression of MT2 protein |
CTD |
PMID:15964310 PMID:16204935 PMID:23573234 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mtmr4 |
myotubularin related protein 4 |
increases expression |
ISO |
cerous chloride results in increased expression of MTMR4 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:74,886,600...74,909,532
Ensembl chr10:74,886,985...74,909,533
|
|
G |
Myadml2 |
myeloid-associated differentiation marker-like 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of MYADML2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:109,822,170...109,827,328
Ensembl chr10:109,825,515...109,827,143
|
|
G |
Myh11 |
myosin heavy chain 11 |
decreases expression |
ISO |
cerous chloride results in decreased expression of MYH11 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:764,421...859,184
Ensembl chr10:764,421...859,184
|
|
G |
Myom3 |
myomesin 3 |
increases expression |
ISO |
cerous chloride results in increased expression of MYOM3 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 5:154,109,293...154,159,943
Ensembl chr 5:154,112,076...154,159,601
|
|
G |
Mysm1 |
myb-like, SWIRM and MPN domains 1 |
increases expression |
ISO |
cerous chloride results in increased expression of MYSM1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 5:113,902,115...113,939,083
Ensembl chr 5:113,906,803...113,939,127
|
|
G |
Nars2 |
asparaginyl-tRNA synthetase 2, mitochondrial |
increases expression |
ISO |
cerous chloride results in increased expression of NARS2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:161,922,132...162,035,817
Ensembl chr 1:161,922,141...162,034,700
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of NCF1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
affects expression multiple interactions |
ISO |
cerous chloride affects the expression of NCF2 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of NCF2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr13:70,226,441...70,259,019
Ensembl chr13:70,226,647...70,257,576
|
|
G |
Ndrg2 |
NDRG family member 2 |
increases expression |
ISO |
cerous chloride results in increased expression of NDRG2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr15:28,305,820...28,314,459
Ensembl chr15:28,305,821...28,314,459
|
|
G |
Ndrg3 |
NDRG family member 3 |
increases expression |
ISO |
cerous chloride results in increased expression of NDRG3 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 3:152,972,055...153,099,089
|
|
G |
Negr1 |
neuronal growth regulator 1 |
increases expression |
ISO |
cerous chloride results in increased expression of NEGR1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:262,914,240...263,650,441
Ensembl chr 2:262,914,327...263,650,441
|
|
G |
Neu1 |
neuraminidase 1 |
decreases expression |
ISO |
cerous chloride results in decreased expression of NEU1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr20:4,610,995...4,615,258
Ensembl chr20:4,610,995...4,615,247
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
increases expression |
ISO |
cerous chloride results in increased expression of NFAT5 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr19:38,446,059...38,533,735
Ensembl chr19:38,446,059...38,533,735
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
cerous chloride results in increased expression of NFKB1 mRNA; cerous chloride results in increased expression of NFKB1 protein |
CTD |
PMID:21656643 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
increases expression |
ISO |
cerous chloride results in increased expression of NFKB2 mRNA; cerous chloride results in increased expression of NFKB2 protein |
CTD |
PMID:21656643 |
|
NCBI chr 1:266,050,634...266,059,277
Ensembl chr 1:266,053,002...266,059,256
|
|
G |
Nfkbib |
NFKB inhibitor beta |
decreases expression |
ISO |
cerous chloride results in decreased expression of NFKBIB mRNA; cerous chloride results in decreased expression of NFKBIB protein |
CTD |
PMID:21656643 |
|
NCBI chr 1:86,941,073...86,948,845
Ensembl chr 1:86,941,074...86,948,845
|
|
G |
Nipbl |
NIPBL, cohesin loading factor |
increases expression |
ISO |
cerous chloride results in increased expression of NIPBL mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:57,508,830...57,676,197
Ensembl chr 2:57,509,428...57,600,820
|
|
G |
Nkd2 |
NKD inhibitor of WNT signaling pathway 2 |
increases expression |
ISO |
cerous chloride results in increased expression of NKD2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:32,054,390...32,085,416
Ensembl chr 1:32,058,044...32,084,877
|
|
G |
Nktr |
natural killer cell triggering receptor |
increases expression |
ISO |
cerous chloride results in increased expression of NKTR mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:130,357,464...130,395,425
Ensembl chr 8:130,366,775...130,393,178
|
|
G |
Nkx6-2 |
NK6 homeobox 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of NKX6-2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:211,922,389...211,923,929
Ensembl chr 1:211,922,389...211,923,929
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
affects expression |
ISO |
cerous chloride affects the expression of NNMT mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 8:52,918,437...52,938,172
Ensembl chr 8:52,925,175...52,937,972
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of NOS2 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of NOS2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
cerous chloride results in increased expression of NR1H3 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Nrbp2 |
nuclear receptor binding protein 2 |
increases expression |
ISO |
cerous chloride results in increased expression of NRBP2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:117,145,106...117,151,694
Ensembl chr 7:117,145,961...117,151,694
|
|
G |
Nrxn3 |
neurexin 3 |
increases expression |
ISO |
cerous chloride results in increased expression of NRXN3 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 6:112,133,204...114,069,589
Ensembl chr 6:112,133,204...114,067,564
|
|
G |
Nt5e |
5' nucleotidase, ecto |
decreases expression |
ISO |
cerous chloride results in decreased expression of NT5E mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
|
|
G |
Ntng2 |
netrin G2 |
increases expression |
ISO |
cerous chloride results in increased expression of NTNG2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 3:7,742,511...7,800,834
Ensembl chr 3:7,742,531...7,796,385
|
|
G |
Nudt1 |
nudix hydrolase 1 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of NUDT1 mRNA cerous chloride results in decreased expression of NUDT1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr12:16,391,578...16,398,771
Ensembl chr12:16,391,578...16,395,029
|
|
G |
Ola1 |
Obg-like ATPase 1 |
increases expression |
ISO |
cerous chloride results in increased expression of OLA1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 3:59,802,007...59,920,935
Ensembl chr 3:59,802,008...59,920,935
|
|
G |
Onecut2 |
one cut homeobox 2 |
increases expression |
ISO |
cerous chloride results in increased expression of ONECUT2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr18:59,830,375...59,882,490
Ensembl chr18:59,830,363...59,875,127
|
|
G |
Pcdhb20 |
protocadherin beta 20 |
increases expression |
ISO |
cerous chloride results in increased expression of PCDHB20 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr18:30,581,530...30,584,905
Ensembl chr18:30,581,530...30,584,905
|
|
G |
Pcna |
proliferating cell nuclear antigen |
affects expression multiple interactions |
ISO |
cerous chloride affects the expression of PCNA protein [cerous chloride co-treated with lanthanum chloride] affects the expression of PCNA protein |
CTD |
PMID:28954213 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pdk2 |
pyruvate dehydrogenase kinase 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of PDK2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:82,838,270...82,852,758
Ensembl chr10:82,839,153...82,852,660
|
|
G |
Per3 |
period circadian regulator 3 |
increases expression |
ISO |
cerous chloride results in increased expression of PER3 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 5:168,088,126...168,123,482
Ensembl chr 5:168,086,998...168,123,395
|
|
G |
Pi16 |
peptidase inhibitor 16 |
decreases expression |
ISO |
cerous chloride results in decreased expression of PI16 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr20:6,923,176...6,932,786
Ensembl chr20:6,923,489...6,932,786
|
|
G |
Plcd1 |
phospholipase C, delta 1 |
increases expression |
ISO |
cerous chloride results in increased expression of PLCD1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 8:127,753,514...127,782,070
Ensembl chr 8:127,753,539...127,782,070
|
|
G |
Pnkp |
polynucleotide kinase 3'-phosphatase |
decreases expression |
ISO |
cerous chloride results in decreased expression of PNKP mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:100,853,475...100,859,202
Ensembl chr 1:100,853,902...100,859,084
|
|
G |
Podxl |
podocalyxin-like |
increases expression |
ISO |
cerous chloride results in increased expression of PODXL mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 4:58,829,049...58,893,353
Ensembl chr 4:58,829,060...58,893,170
|
|
G |
Prdx1 |
peroxiredoxin 1 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of PRDX1 mRNA cerous chloride results in decreased expression of PRDX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 5:135,536,413...135,551,986
Ensembl chr 5:135,536,413...135,551,990
|
|
G |
Prdx2 |
peroxiredoxin 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of PRDX2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr19:26,084,816...26,090,095
Ensembl chr19:26,084,903...26,090,094
|
|
G |
Prdx5 |
peroxiredoxin 5 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of PRDX5 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:222,164,462...222,167,447
Ensembl chr 1:222,164,462...222,167,447
|
|
G |
Prex1 |
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of PREX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:163,329,580...163,477,822
Ensembl chr 3:163,329,975...163,477,715
|
|
G |
Prpf38b |
pre-mRNA processing factor 38B |
increases expression |
ISO |
cerous chloride results in increased expression of PRPF38B mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:211,706,245...211,715,271
Ensembl chr 2:211,706,228...211,715,311
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of PTGS2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Pth2 |
parathyroid hormone 2 |
increases expression |
ISO |
cerous chloride results in increased expression of PTH2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:101,175,499...101,179,001
Ensembl chr 1:101,178,104...101,178,753
|
|
G |
Ptpa |
protein phosphatase 2 phosphatase activator |
increases expression |
ISO |
cerous chloride results in increased expression of PTPA mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 3:8,982,122...9,012,585
Ensembl chr 3:8,982,122...9,012,585
|
|
G |
Pxdn |
peroxidasin |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of PXDN mRNA cerous chloride results in decreased expression of PXDN mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:48,866,496...48,982,368
Ensembl chr 6:48,866,601...48,980,340
|
|
G |
Rapgefl1 |
Rap guanine nucleotide exchange factor like 1 |
increases expression |
ISO |
cerous chloride results in increased expression of RAPGEFL1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:86,749,220...86,765,677
Ensembl chr10:86,763,117...86,765,675
|
|
G |
Rbm8a |
RNA binding motif protein 8A |
decreases expression |
ISO |
cerous chloride results in decreased expression of RBM8A mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:198,755,261...198,758,028
Ensembl chr 2:198,755,262...198,758,028
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression |
ISO |
cerous chloride results in increased expression of RELA mRNA; cerous chloride results in increased expression of RELA protein |
CTD |
PMID:21656643 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Retsat |
retinol saturase |
decreases expression |
ISO |
cerous chloride results in decreased expression of RETSAT mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 4:100,465,365...100,474,128
Ensembl chr 4:100,465,170...100,474,301
|
|
G |
Rgs11 |
regulator of G-protein signaling 11 |
increases expression |
ISO |
cerous chloride results in increased expression of RGS11 mRNA |
CTD |
PMID:23573234 |
|
|
|
G |
Rpgrip1l |
Rpgrip1-like |
decreases expression |
ISO |
cerous chloride results in decreased expression of RPGRIP1L mRNA |
CTD |
PMID:23573234 |
|
NCBI chr19:17,115,266...17,208,055
Ensembl chr19:17,115,412...17,208,055
|
|
G |
Rtl1 |
retrotransposon-like 1 |
increases expression |
ISO |
cerous chloride results in increased expression of RTL1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 6:133,710,207...133,721,191
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
ISO |
cerous chloride results in increased expression of S100A8 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
cerous chloride results in increased expression of S100A9 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Sat2 |
spermidine/spermine N1-acetyltransferase family member 2 |
increases expression |
ISO |
cerous chloride results in increased expression of SAT2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:56,227,703...56,229,796
Ensembl chr10:56,227,692...56,229,850
|
|
G |
Scara3 |
scavenger receptor class A, member 3 |
decreases expression |
ISO |
cerous chloride results in decreased expression of SCARA3 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr15:42,605,505...42,638,409
Ensembl chr15:42,605,473...42,638,392
|
|
G |
Scgb1a1 |
secretoglobin family 1A member 1 |
increases expression |
ISO |
cerous chloride results in increased expression of SCGB1A1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:225,279,698...225,283,246
Ensembl chr 1:225,279,676...225,283,326
|
|
G |
Selenop |
selenoprotein P |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SELENOP mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 2:53,105,912...53,116,198
Ensembl chr 2:53,109,684...53,114,858
|
|
G |
Sf1 |
splicing factor 1 |
increases expression |
ISO |
cerous chloride results in increased expression of SF1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:221,735,512...221,749,216
Ensembl chr 1:221,735,517...221,749,086
|
|
G |
Sfpq |
splicing factor proline and glutamine rich |
increases expression |
ISO |
cerous chloride results in increased expression of SFPQ mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 5:145,079,803...145,088,517
Ensembl chr 5:145,079,803...145,088,498
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions decreases expression increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SIRT2 mRNA cerous chloride results in decreased expression of SIRT2 mRNA cerous chloride results in increased expression of SIRT2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:86,948,866...86,971,954
Ensembl chr 1:86,948,918...86,971,952
|
|
G |
Sirt7 |
sirtuin 7 |
decreases expression |
ISO |
cerous chloride results in decreased expression of SIRT7 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:109,796,046...109,802,821
Ensembl chr10:109,796,020...109,802,739
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
decreases expression |
ISO |
cerous chloride results in decreased expression of SLC5A7 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 9:5,294,377...5,330,822
Ensembl chr 9:5,294,381...5,330,815
|
|
G |
Smpdl3b |
sphingomyelin phosphodiesterase, acid-like 3B |
decreases expression |
ISO |
cerous chloride results in decreased expression of SMPDL3B mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 5:150,925,150...150,946,994
Ensembl chr 5:150,925,370...150,949,931
|
|
G |
Sncb |
synuclein, beta |
increases expression |
ISO |
cerous chloride results in increased expression of SNCB mRNA |
CTD |
PMID:23573234 |
|
NCBI chr17:10,384,472...10,392,776
Ensembl chr17:10,384,511...10,392,843
|
|
G |
Sntb2 |
syntrophin, beta 2 |
increases expression |
ISO |
cerous chloride results in increased expression of SNTB2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr19:39,126,589...39,209,152
Ensembl chr19:39,126,589...39,209,152
|
|
G |
Snu13 |
small nuclear ribonucleoprotein 13 |
decreases expression |
ISO |
cerous chloride results in decreased expression of SNU13 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:123,282,754...123,287,721
Ensembl chr 7:123,282,754...123,287,721
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases activity |
ISO |
cerous chloride results in decreased activity of SOD1 protein |
CTD |
PMID:15964310 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases activity multiple interactions |
ISO |
cerous chloride results in decreased activity of SOD2 protein [cerous chloride co-treated with lanthanum chloride] results in increased expression of SOD2 mRNA |
CTD |
PMID:15964310 PMID:28954213 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Spry4 |
sprouty RTK signaling antagonist 4 |
increases expression |
ISO |
cerous chloride results in increased expression of SPRY4 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr18:32,593,370...32,609,890
Ensembl chr18:32,594,958...32,609,864
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions affects expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SQSTM1 mRNA cerous chloride affects the expression of SQSTM1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srr |
serine racemase |
increases expression |
ISO |
cerous chloride results in increased expression of SRR mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:61,756,138...61,772,327
Ensembl chr10:61,756,138...61,772,293
|
|
G |
Srxn1 |
sulfiredoxin 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SRXN1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
|
|
G |
Stk25 |
serine/threonine kinase 25 |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of STK25 mRNA [cerous chloride co-treated with lanthanum chloride] results in decreased expression of STK25 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 9:100,767,578...100,779,715
Ensembl chr 9:100,767,579...100,779,715
|
|
G |
Strbp |
spermatid perinuclear RNA binding protein |
increases expression |
ISO |
cerous chloride results in increased expression of STRBP mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 3:21,817,680...21,956,988
Ensembl chr 3:21,828,298...21,904,270
|
|
G |
Sumo3 |
small ubiquitin-like modifier 3 |
increases expression |
ISO |
cerous chloride results in increased expression of SUMO3 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr20:11,726,488...11,737,050
Ensembl chr20:11,726,497...11,737,050
|
|
G |
Syne4 |
spectrin repeat containing nuclear envelope family member 4 |
increases expression |
ISO |
cerous chloride results in increased expression of SYNE4 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:88,772,729...88,777,044
Ensembl chr 1:88,772,904...88,776,999 Ensembl chr 1:88,772,904...88,776,999
|
|
G |
Tenm2 |
teneurin transmembrane protein 2 |
increases expression |
ISO |
cerous chloride results in increased expression of TENM2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:20,846,091...21,791,771
Ensembl chr10:20,844,899...21,265,026
|
|
G |
Tfdp1 |
transcription factor Dp-1 |
increases expression |
ISO |
cerous chloride results in increased expression of TFDP1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr16:81,088,642...81,127,244
Ensembl chr16:81,089,292...81,127,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
cerous chloride results in increased expression of TGFB1 |
CTD |
PMID:23712967 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tia1 |
TIA1 cytotoxic granule-associated RNA binding protein |
increases expression |
ISO |
cerous chloride results in increased expression of TIA1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 4:118,207,845...118,238,246
Ensembl chr 4:118,207,862...118,235,218
|
|
G |
Tll1 |
tolloid-like 1 |
decreases expression |
ISO |
cerous chloride results in decreased expression of TLL1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr16:27,399,467...27,597,240
Ensembl chr16:27,399,467...27,597,240
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression |
ISO |
cerous chloride results in increased expression of TLR2 mRNA; cerous chloride results in increased expression of TLR2 protein |
CTD |
PMID:21656643 |
|
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression |
ISO |
cerous chloride results in increased expression of TLR4 mRNA; cerous chloride results in increased expression of TLR4 protein |
CTD |
PMID:21656643 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tmem219 |
transmembrane protein 219 |
increases expression |
ISO |
cerous chloride results in increased expression of TMEM219 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:198,322,276...198,360,552
Ensembl chr 1:198,324,857...198,354,466
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
cerous chloride results in increased expression of TNF; cerous chloride results in increased expression of TNF mRNA; cerous chloride results in increased expression of TNF protein |
CTD |
PMID:21656643 PMID:23712967 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnks2 |
tankyrase 2 |
increases expression |
ISO |
cerous chloride results in increased expression of TNKS2 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 1:255,478,794...255,532,143
Ensembl chr 1:255,479,261...255,532,143
|
|
G |
Trps1 |
transcriptional repressor GATA binding 1 |
increases expression |
ISO |
cerous chloride results in increased expression of TRPS1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:90,085,895...90,320,430
Ensembl chr 7:90,090,828...90,318,221
|
|
G |
Tspoap1 |
TSPO associated protein 1 |
increases expression |
ISO |
cerous chloride results in increased expression of TSPOAP1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr10:75,053,956...75,079,615
Ensembl chr10:75,055,020...75,076,434
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
cerous chloride results in increased expression of TXN mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
cerous chloride results in increased expression of TXNRD1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Txnrd2 |
thioredoxin reductase 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of TXNRD2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr11:86,667,994...86,716,063
Ensembl chr11:86,667,997...86,716,254
|
|
G |
Ube2v1 |
ubiquitin conjugating enzyme E2 V1 |
increases expression |
ISO |
cerous chloride results in increased expression of UBE2V1 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 3:164,343,833...164,366,684
Ensembl chr 3:164,343,833...164,366,684
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] affects the expression of UCP2 mRNA cerous chloride results in decreased expression of UCP2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Unc13b |
unc-13 homolog B |
increases expression |
ISO |
cerous chloride results in increased expression of UNC13B mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 5:58,505,449...58,714,396
Ensembl chr 5:58,505,500...58,715,576
|
|
G |
Uqcrb |
ubiquinol-cytochrome c reductase binding protein |
increases expression |
ISO |
cerous chloride results in increased expression of UQCRB mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 7:71,264,501...71,269,869
Ensembl chr 7:71,264,514...71,269,869 Ensembl chr 1:71,264,514...71,269,869
|
|
G |
Vmac |
vimentin-type intermediate filament associated coiled-coil protein |
increases expression |
ISO |
cerous chloride results in increased expression of VMAC mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 9:10,338,260...10,341,903
Ensembl chr 9:10,339,075...10,340,329
|
|
G |
Zap70 |
zeta chain of T cell receptor associated protein kinase 70 |
affects expression |
ISO |
cerous chloride affects the expression of ZAP70 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 9:43,331,149...43,353,097
Ensembl chr 9:43,331,155...43,353,113
|
|
G |
Zfp24 |
zinc finger protein 24 |
increases expression |
ISO |
cerous chloride results in increased expression of ZNF24 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr18:15,910,175...15,921,757
Ensembl chr18:15,914,399...15,921,734
|
|
G |
Zfp35 |
zinc finger protein 35 |
decreases expression |
ISO |
cerous chloride results in decreased expression of ZFP35 mRNA |
CTD |
PMID:23573234 |
|
NCBI chr18:15,883,182...15,898,803
Ensembl chr18:15,883,182...15,898,821
|
|
G |
Zfp512b |
zinc finger protein 512B |
increases expression |
ISO |
cerous chloride results in increased expression of ZNF512B mRNA |
CTD |
PMID:23573234 |
|
NCBI chr 3:177,078,708...177,089,210
Ensembl chr 3:177,078,709...177,089,199
|
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Erbium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:82,129,071...82,197,828
Ensembl chr10:82,129,506...82,197,848
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
gadodiamide results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19561517 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
ISO |
gadodiamide results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Ankrd22 |
ankyrin repeat domain 22 |
increases expression |
ISO |
gadodiamide results in increased expression of ANKRD22 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:252,430,750...252,461,346
Ensembl chr 1:252,429,677...252,461,461
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression |
ISO |
gadodiamide results in increased expression of ATM mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases expression |
ISO |
gadodiamide results in increased expression of ATP8B1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr18:60,013,388...60,152,920
Ensembl chr18:60,013,382...60,095,354
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression increases secretion |
ISO EXP |
gadodiamide results in increased expression of CCL2 mRNA gadodiamide results in increased expression of CCL2 mRNA; gadodiamide results in increased expression of CCL2 protein gadodiamide results in increased secretion of CCL2 protein |
CTD |
PMID:20938346 PMID:20959327 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression |
EXP |
gadodiamide results in increased expression of CCL4 protein |
CTD |
PMID:20938346 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
EXP |
gadodiamide results in increased expression of CCL7 protein |
CTD |
PMID:20938346 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression increases secretion |
ISO EXP |
gadodiamide results in increased expression of CXCL10 mRNA gadodiamide results in increased expression of CXCL10 protein gadodiamide results in increased secretion of CXCL10 protein |
CTD |
PMID:20938346 PMID:20959327 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases secretion increases expression |
ISO |
gadodiamide results in increased secretion of CXCL11 protein gadodiamide results in increased expression of CXCL11 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
gadodiamide results in increased expression of CXCL12 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
increases expression |
ISO |
gadodiamide results in increased expression of CXCL9 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression |
ISO |
gadodiamide results in increased expression of IDO1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr16:72,216,326...72,228,098
Ensembl chr16:72,216,326...72,228,098
|
|
G |
Ifi44l |
interferon-induced protein 44-like |
increases expression |
ISO |
gadodiamide results in increased expression of IFI44L mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 2:256,948,722...256,979,573
Ensembl chr 2:256,964,860...256,978,668
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
ISO |
gadodiamide results in increased expression of IFIT3 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:252,906,234...252,911,377
Ensembl chr 1:252,906,234...252,911,382
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
gadodiamide results in increased expression of IFNG mRNA; gadodiamide results in increased expression of IFNG protein |
CTD |
PMID:19404939 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il13 |
interleukin 13 |
increases expression |
ISO |
gadodiamide results in increased expression of IL13 mRNA; gadodiamide results in increased expression of IL13 protein |
CTD |
PMID:19404939 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
EXP |
gadodiamide results in increased expression of IL1A protein |
CTD |
PMID:20938346 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il4 |
interleukin 4 |
increases expression affects expression |
ISO |
gadodiamide results in increased expression of IL4 protein gadodiamide affects the expression of IL4 mRNA |
CTD |
PMID:19404939 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il4i1 |
interleukin 4 induced 1 |
increases expression |
ISO |
gadodiamide results in increased expression of IL4I1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:100,811,727...100,836,901
Ensembl chr 1:100,830,064...100,836,677
|
|
G |
Il6 |
interleukin 6 |
affects expression increases expression |
ISO |
gadodiamide affects the expression of IL6 protein gadodiamide results in increased expression of IL6 mRNA |
CTD |
PMID:19404939 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kitlg |
KIT ligand |
increases expression |
EXP |
gadodiamide results in increased expression of KITLG protein |
CTD |
PMID:20938346 |
|
NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19561517 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19561517 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of MMP1 protein] gadodiamide results in increased expression of MMP1 mRNA; gadodiamide results in increased expression of MMP1 protein |
CTD |
PMID:19561517 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
ISO |
gadodiamide results in increased expression of NOS2 protein |
CTD |
PMID:20959327 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nxpe3 |
neurexophilin and PC-esterase domain family, member 3 |
increases expression |
ISO |
gadodiamide results in increased expression of NXPE3 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr11:47,188,332...47,238,372
Ensembl chr11:47,188,495...47,238,372
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases localization |
ISO |
gadodiamide results in increased localization of RELA protein |
CTD |
PMID:20959327 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
RGD1306063 |
similar to HT021 |
increases expression |
ISO |
gadodiamide results in increased expression of C3ORF14 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr15:12,869,217...12,889,144
Ensembl chr15:12,872,408...12,889,108
|
|
G |
Rhoq |
ras homolog family member Q |
increases expression |
ISO |
gadodiamide results in increased expression of RHOQ mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 6:10,533,151...10,568,582
Ensembl chr 6:10,533,151...10,568,581
|
|
G |
Rit1 |
Ras-like without CAAX 1 |
increases expression |
ISO |
gadodiamide results in increased expression of RIT1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 2:188,087,486...188,099,444
Ensembl chr 2:188,087,486...188,099,444
|
|
G |
Rnf125 |
ring finger protein 125 |
increases expression |
ISO |
gadodiamide results in increased expression of RNF125 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr18:15,193,226...15,225,454
Ensembl chr18:15,192,962...15,225,427
|
|
G |
Rsad2 |
radical S-adenosyl methionine domain containing 2 |
increases expression |
ISO |
gadodiamide results in increased expression of RSAD2 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 6:45,655,947...45,669,083
Ensembl chr 6:45,655,954...45,669,148
|
|
G |
Slc39a10 |
solute carrier family 39 member 10 |
increases expression |
ISO |
gadodiamide results in increased expression of SLC39A10 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 9:59,947,562...60,070,549
Ensembl chr 9:60,021,534...60,070,552
|
|
G |
Spn |
sialophorin |
increases expression |
ISO |
gadodiamide results in increased expression of SPN mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:198,572,999...198,585,664
Ensembl chr 1:198,572,999...198,577,226
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
EXP |
gadodiamide results in increased expression of SPP1 protein |
CTD |
PMID:20938346 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO EXP |
gadodiamide results in increased expression of TGFB1 mRNA; gadodiamide results in increased expression of TGFB1 protein |
CTD |
PMID:19404939 PMID:20938346 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO EXP |
gadodiamide results in increased expression of TIMP1 mRNA; gadodiamide results in increased expression of TIMP1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [gadodiamide results in increased expression of TIMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of TIMP1 protein] |
CTD |
PMID:19561517 PMID:20938346 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Ubd |
ubiquitin D |
increases expression |
ISO |
gadodiamide results in increased expression of UBD mRNA |
CTD |
PMID:20959327 |
|
NCBI chr20:1,876,175...1,878,126
Ensembl chr20:1,876,173...1,897,814
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO EXP |
gadodiamide results in increased expression of VEGFA mRNA; gadodiamide results in increased expression of VEGFA protein |
CTD |
PMID:19404939 PMID:20938346 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Wdr5 |
WD repeat domain 5 |
increases expression |
ISO |
gadodiamide results in increased expression of WDR5 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 3:6,061,892...6,080,724
Ensembl chr 3:6,061,940...6,080,680
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases expression |
ISO |
gadodiamide results in increased expression of XIAP mRNA |
CTD |
PMID:20959327 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
G |
Zfp652 |
zinc finger protein 652 |
increases expression |
ISO |
gadodiamide results in increased expression of ZNF652 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr10:83,556,809...83,572,014
Ensembl chr10:83,556,809...83,572,019
|
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:82,129,071...82,197,828
Ensembl chr10:82,129,506...82,197,848
|
|
G |
Casp3 |
caspase 3 |
increases activity |
EXP |
Gadolinium results in increased activity of CASP3 protein |
CTD |
PMID:20398695 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions |
EXP |
[Gadolinium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Gadolinium binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Gadolinium binds to and results in increased activity of CASR protein; Gadolinium inhibits the reaction [Calcium binds to and results in increased activity of CASR protein] |
CTD |
PMID:10231437 PMID:11071898 |
|
NCBI chr11:67,188,204...67,262,261
Ensembl chr11:67,188,630...67,258,771
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]] |
CTD |
PMID:21127073 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:18316702 |
|
NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [Glucose results in increased expression of DDIT3 protein] |
CTD |
PMID:30076216 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
Gadolinium inhibits the reaction [SCH 23390 binds to DRD1 protein] |
CTD |
PMID:9109525 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
Gadolinium inhibits the reaction [3-N-methylspiperone binds to DRD2 protein] |
CTD |
PMID:9109525 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Gnaq |
G protein subunit alpha q |
increases response to substance |
ISO |
GNAQ protein results in increased susceptibility to Gadolinium |
CTD |
PMID:15068510 |
|
NCBI chr 1:233,382,778...233,622,584
Ensembl chr 1:233,382,708...233,622,786
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [Glucose results in increased expression of HSPA5 protein] |
CTD |
PMID:30076216 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Ift88 |
intraflagellar transport 88 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [IFT88 protein mutant form results in increased uptake of Calcium] |
CTD |
PMID:16396941 |
|
NCBI chr15:37,690,417...37,786,855
Ensembl chr15:37,691,345...37,784,924
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; Gadolinium inhibits the reaction [Calcimycin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11914123 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; Gadolinium inhibits the reaction [Calcimycin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11914123 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
affects response to substance |
ISO |
S100A6 protein affects the susceptibility to Gadolinium |
CTD |
PMID:15068510 |
|
NCBI chr 2:190,007,013...190,008,512
Ensembl chr 2:190,007,216...190,008,511
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein] |
CTD |
PMID:15843607 |
|
NCBI chr 5:3,783,247...3,836,485
Ensembl chr 5:3,783,247...3,836,485
|
|
G |
Trpc3 |
transient receptor potential cation channel, subfamily C, member 3 |
multiple interactions |
ISO |
Gadolinium affects the localization of and results in decreased activity of TRPC3 protein |
CTD |
PMID:16522635 |
|
NCBI chr 2:123,329,954...123,467,574
Ensembl chr 2:123,329,875...123,407,496
|
|
G |
Trpc5 |
transient receptor potential cation channel, subfamily C, member 5 |
multiple interactions |
ISO |
2-aminoethoxydiphenyl borate promotes the reaction [resveratrol inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]]; Ascorbic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; Calcium promotes the reaction [resveratrol inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]]; CAT protein inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]; Gallic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; resveratrol inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; resveratrol promotes the reaction [Ascorbic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]] |
CTD |
PMID:21127073 |
|
NCBI chr X:115,624,670...115,908,248
Ensembl chr X:115,627,653...115,908,693
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
decreases activity |
ISO |
Gadolinium results in decreased activity of TRPC6 protein |
CTD |
PMID:11179201 |
|
NCBI chr 8:6,811,543...6,917,534
Ensembl chr 8:6,811,543...6,917,535
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Calcium]] |
CTD |
PMID:11988098 |
|
NCBI chr 1:234,478,908...234,631,264
Ensembl chr 1:234,479,289...234,596,971
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
multiple interactions decreases activity |
EXP |
[Gadolinium results in decreased activity of TRPV4 protein] which results in decreased susceptibility to Buthionine Sulfoximine |
CTD |
PMID:20064552 |
|
NCBI chr12:47,698,915...47,737,902
Ensembl chr12:47,698,947...47,737,902
|
|
G |
Trpv6 |
transient receptor potential cation channel, subfamily V, member 6 |
multiple interactions increases uptake |
ISO |
Gadolinium inhibits the reaction [TRPV6 protein results in increased uptake of Calcium] TRPV6 protein results in increased uptake of Gadolinium |
CTD |
PMID:21146870 |
|
NCBI chr 4:70,918,631...70,934,291
Ensembl chr 4:70,918,632...70,934,295
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [perfluorodecanoic acid results in increased expression of ABCC4 mRNA] |
CTD |
PMID:18757529 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
gadolinium chloride promotes the reaction [Ethanol results in decreased expression of ACACA protein] |
CTD |
PMID:28882574 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [perfluoro-n-nonanoic acid results in increased expression of ACOT1 mRNA] |
CTD |
PMID:22648072 |
|
NCBI chr 6:107,485,088...107,493,082
Ensembl chr 6:107,485,249...107,493,798
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:11408273 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
EXP ISO |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of ADGRE1 mRNA gadolinium chloride inhibits the reaction [Ethanol results in increased expression of ADGRE1 protein] |
CTD |
PMID:25813056 PMID:28882574 |
|
NCBI chr 9:9,431,888...9,585,883
Ensembl chr 9:9,431,860...9,585,865
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of APOB mRNA] |
CTD |
PMID:25813056 |
|
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
|
|
G |
Atf4 |
activating transcription factor 4 |
affects expression |
EXP |
gadolinium chloride affects the expression of ATF4 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression affects expression |
EXP |
Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of ATF6 protein] gadolinium chloride affects the expression of ATF6 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [Carbon Tetrachloride results in increased expression of BMP2 mRNA] |
CTD |
PMID:17158861 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein] |
CTD |
PMID:12516873 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA]; gadolinium chloride inhibits the reaction [[Fructose co-treated with Copper deficiency] results in increased expression of CCL2 protein] |
CTD |
PMID:25813056 PMID:26177832 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
gadolinium chloride results in increased expression of CCNE1 |
CTD |
PMID:19184457 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cd163 |
CD163 molecule |
multiple interactions |
EXP |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of CD163 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA] |
CTD |
PMID:25813056 PMID:26177832 |
|
NCBI chr 4:156,752,063...156,785,467
Ensembl chr 4:156,752,082...156,785,467
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
ISO EXP |
gadolinium chloride inhibits the reaction [[Dietary Fats co-treated with bromodichloromethane] results in increased expression of CD68 mRNA] [gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of CD68 mRNA; [gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of CD68 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA] |
CTD |
PMID:23438451 PMID:25813056 PMID:26177832 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [perfluoro-n-nonanoic acid results in increased expression of CPT1A mRNA] |
CTD |
PMID:22648072 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
gadolinium chloride inhibits the reaction [[Progesterone co-treated with Halothane] results in increased expression of CXCL2 mRNA] gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA] |
CTD |
PMID:22157104 PMID:26177832 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of CXCL1 mRNA]]; gadolinium chloride inhibits the reaction [Progesterone results in increased expression of CXCL1 mRNA] |
CTD |
PMID:22157104 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP1A2 protein] |
CTD |
PMID:18202523 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Phenobarbital results in increased expression of CYP2B1 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2B1 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2B1 protein] |
CTD |
PMID:10918498 PMID:18202523 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2B2 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2B2 protein] |
CTD |
PMID:18202523 |
|
NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased activity of and results in decreased expression of CYP2C11 protein] |
CTD |
PMID:18079364 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2E1 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2E1 protein] |
CTD |
PMID:18202523 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP3A2 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP3A2 protein]; gadolinium chloride inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased activity of and results in decreased expression of CYP3A2 protein] |
CTD |
PMID:18079364 PMID:18202523 |
|
NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of CYP4A1 mRNA] |
CTD |
PMID:25813056 |
|
NCBI chr 5:134,492,734...134,507,158
Ensembl chr 5:134,492,756...134,507,154
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression affects expression |
EXP |
Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of DDIT3 protein] gadolinium chloride affects the expression of DDIT3 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression |
EXP |
gadolinium chloride results in increased expression of EIF2AK3 protein |
CTD |
PMID:21198628 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of ERN1 protein] |
CTD |
PMID:21198628 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP ISO |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of FASN mRNA gadolinium chloride promotes the reaction [Ethanol results in decreased expression of FASN protein] |
CTD |
PMID:25813056 PMID:28882574 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein]; gadolinium chloride inhibits the reaction [Vitamin A results in increased activity of GPT protein] gadolinium chloride inhibits the reaction [Amiodarone promotes the reaction [Dexamethasone results in increased expression of GPT protein]] |
CTD |
PMID:8627517 PMID:25900201 PMID:26177832 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression |
EXP |
gadolinium chloride results in increased expression of HAMP |
CTD |
PMID:19721414 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hjv |
hemojuvelin BMP co-receptor |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of HJV |
CTD |
PMID:19721414 |
|
NCBI chr 2:198,655,437...198,659,318
Ensembl chr 2:198,655,437...198,659,317
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein] |
CTD |
PMID:26177832 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of HMGCS2 mRNA] |
CTD |
PMID:25813056 |
|
NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of HSPA1A mRNA]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of HSPA1A protein] |
CTD |
PMID:12963478 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions affects expression |
EXP |
gadolinium chloride results in increased expression of HSPA5 protein Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of HSPA5 protein] gadolinium chloride affects the expression of HSPA5 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [[Progesterone co-treated with Halothane] results in increased expression of ICAM1 mRNA] |
CTD |
PMID:22157104 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ifng |
interferon gamma |
affects expression increases expression |
ISO |
gadolinium chloride affects the expression of IFNG protein gadolinium chloride results in increased expression of IFNG mRNA |
CTD |
PMID:15590129 PMID:19404939 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Lipopolysaccharides results in decreased expression of IGF1 protein] |
CTD |
PMID:16522730 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Lipopolysaccharides results in decreased expression of IGFBP3 protein] |
CTD |
PMID:16522730 |
|
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA]; gadolinium chloride inhibits the reaction [perfluoro-n-nonanoic acid results in decreased expression of IL10 protein] |
CTD |
PMID:22648072 PMID:26177832 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il13 |
interleukin 13 |
increases expression |
ISO |
gadolinium chloride results in increased expression of IL13 mRNA |
CTD |
PMID:19404939 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of IL1A mRNA]; gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of IL1A protein] |
CTD |
PMID:15025948 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
gadolinium chloride results in increased expression of IL1B [gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of IL1B mRNA; gadolinium chloride inhibits the reaction [perfluoro-n-nonanoic acid results in increased expression of IL1B protein] |
CTD |
PMID:19721414 PMID:22648072 PMID:25813056 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il4 |
interleukin 4 |
affects expression |
ISO |
gadolinium chloride affects the expression of IL4 mRNA; gadolinium chloride affects the expression of IL4 protein |
CTD |
PMID:19404939 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
EXP ISO |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of IL6 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA]; gadolinium chloride inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] gadolinium chloride inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] gadolinium chloride results in increased expression of IL6 gadolinium chloride results in increased expression of IL6 mRNA |
CTD |
PMID:12127824 PMID:12963478 PMID:19404939 PMID:19721414 PMID:24849676 PMID:25813056 PMID:26177832 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Lipe |
lipase E, hormone sensitive type |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Ethanol results in increased phosphorylation of LIPE protein] |
CTD |
PMID:28882574 |
|
NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
|
|
G |
Ltb |
lymphotoxin beta |
increases expression |
ISO |
gadolinium chloride results in increased expression of LTB mRNA |
CTD |
PMID:15590129 |
|
NCBI chr20:5,184,631...5,186,476
Ensembl chr20:5,184,515...5,186,503 Ensembl chr20:5,184,515...5,186,503
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions increases activity |
ISO EXP |
gadolinium chloride results in decreased phosphorylation of MAPK1 protein gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein] gadolinium chloride results in increased activity of MAPK1 protein Pertussis Toxin inhibits the reaction [gadolinium chloride results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:12493575 PMID:21605080 PMID:26177832 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases activity |
ISO EXP |
gadolinium chloride results in decreased phosphorylation of MAPK3 protein gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein] Pertussis Toxin inhibits the reaction [gadolinium chloride results in decreased phosphorylation of MAPK3 protein] gadolinium chloride results in increased activity of MAPK3 protein |
CTD |
PMID:12493575 PMID:21605080 PMID:26177832 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions increases expression |
EXP |
[Dimethylnitrosamine co-treated with gadolinium chloride] results in increased expression of MMP13 mRNA; SB 203580 inhibits the reaction [gadolinium chloride results in increased expression of MMP13 mRNA] |
CTD |
PMID:12493575 |
|
NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions increases expression |
EXP |
[Dimethylnitrosamine co-treated with gadolinium chloride] results in increased expression of MMP14 mRNA gadolinium chloride results in increased expression of MMP14 mRNA; gadolinium chloride results in increased expression of MMP14 protein |
CTD |
PMID:12493575 |
|
NCBI chr15:33,074,441...33,083,666
Ensembl chr15:33,074,441...33,083,655
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
EXP |
gadolinium chloride results in increased expression of MMP9 mRNA SB 203580 inhibits the reaction [gadolinium chloride results in increased expression of MMP9 mRNA] |
CTD |
PMID:12493575 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Thioacetamide results in increased activity of MPO protein] |
CTD |
PMID:12963478 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased activity of NFKB1 protein] |
CTD |
PMID:15025948 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
EXP |
gadolinium chloride results in increased expression of NOS2 mRNA |
CTD |
PMID:15135310 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of PDGFA mRNA |
CTD |
PMID:14578756 |
|
NCBI chr12:17,734,141...17,756,186
Ensembl chr12:17,734,133...17,755,285
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of PDGFB mRNA |
CTD |
PMID:14578756 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [perfluoro-n-nonanoic acid results in increased expression of PPARA mRNA] |
CTD |
PMID:22648072 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
increases activity |
ISO |
gadolinium chloride results in increased activity of PTK2 |
CTD |
PMID:19184457 |
|
NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases phosphorylation |
ISO |
gadolinium chloride results in increased phosphorylation of RB1 protein |
CTD |
PMID:19184457 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased activity of RELA protein] |
CTD |
PMID:15025948 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
EXP ISO |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of SCD1 mRNA] gadolinium chloride promotes the reaction [Ethanol results in decreased expression of SCD1 protein] |
CTD |
PMID:25813056 PMID:28882574 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of SLC40A1 |
CTD |
PMID:19721414 |
|
NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Fructose co-treated with Copper deficiency] results in increased expression of SREBF1 protein] |
CTD |
PMID:25813056 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression affects expression |
EXP ISO |
gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] gadolinium chloride results in increased expression of TGFB1 protein gadolinium chloride results in increased expression of TGFB1 mRNA gadolinium chloride affects the expression of TGFB1 mRNA |
CTD |
PMID:11408273 PMID:15590129 PMID:15964588 PMID:19404939 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of TLR4 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein] |
CTD |
PMID:25813056 PMID:26177832 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression increases expression |
EXP ISO |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of TNF mRNA; gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of TNF mRNA]; gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of TNF protein]; gadolinium chloride inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; gadolinium chloride inhibits the reaction [perfluoro-n-nonanoic acid results in increased expression of TNF protein]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of TNF protein] gadolinium trichloride inhibits the reaction [estriol enhances the reaction [lipopolysaccharide increases expression of Tnf mRNA in liver]] gadolinium chloride inhibits the reaction [lead acetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; gadolinium chloride inhibits the reaction [perfluorodecanoic acid results in increased expression of TNF protein] gadolinium chloride results in increased expression of TNF gadolinium chloride results in increased expression of TNF mRNA |
CTD |
PMID:12127824 PMID:12963478 PMID:14687926 PMID:15025948 PMID:15590129 PMID:16581537 PMID:18757529 PMID:19721414 PMID:22648072 PMID:25813056, PMID:9575848 |
RGD:15017096 |
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression |
ISO |
gadolinium chloride results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:21605080 |
|
NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
gadolinium chloride results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:15590129 |
|
NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases expression |
ISO |
gadolinium chloride results in increased expression of TNFSF10 mRNA |
CTD |
PMID:15590129 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression |
ISO |
gadolinium chloride results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:21605080 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of UCP2 mRNA] |
CTD |
PMID:18314881 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
gadolinium chloride results in increased expression of VEGFA mRNA; gadolinium chloride results in increased expression of VEGFA protein |
CTD |
PMID:19404939 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases splicing |
EXP |
gadolinium chloride results in increased splicing of XBP1 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Holmium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:82,129,071...82,197,828
Ensembl chr10:82,129,506...82,197,848
|
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Lanthanum inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:82,129,071...82,197,828
Ensembl chr10:82,129,506...82,197,848
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases phosphorylation |
EXP |
Lanthanum results in decreased phosphorylation of CAMK4 protein |
CTD |
PMID:21695898 |
|
NCBI chr18:25,746,878...25,975,962
Ensembl chr18:25,749,098...25,965,957
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions |
ISO |
Lanthanum inhibits the reaction [Calcium binds to and results in increased activity of CASR protein]; Lanthanum inhibits the reaction [CASR protein results in increased uptake of Calcium]; Lanthanum inhibits the reaction [Spermine binds to and results in increased activity of CASR protein] |
CTD |
PMID:17041782 PMID:21562303 |
|
NCBI chr11:67,188,204...67,262,261
Ensembl chr11:67,188,630...67,258,771
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
Lanthanum inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:18316702 |
|
NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases phosphorylation |
EXP |
Lanthanum results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:21695898 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
Lanthanum inhibits the reaction [SCH 23390 binds to DRD1 protein] |
CTD |
PMID:9109525 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
Lanthanum inhibits the reaction [3-N-methylspiperone binds to DRD2 protein] |
CTD |
PMID:9109525 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
EXP |
Lanthanum results in decreased expression of EGR1 mRNA |
CTD |
PMID:21695898 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
Lanthanum results in decreased expression of FOS mRNA |
CTD |
PMID:21695898 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
[delta-hexachlorocyclohexane co-treated with Lanthanum] promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]]; Lanthanum promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]] |
CTD |
PMID:9316872 |
|
NCBI chr10:27,310,718...27,371,802
Ensembl chr10:27,310,725...27,366,665
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
multiple interactions |
ISO |
[delta-hexachlorocyclohexane co-treated with Lanthanum] promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]]; Lanthanum promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]] |
CTD |
PMID:9316872 |
|
NCBI chr 1:113,034,251...113,265,364
Ensembl chr 1:112,976,770...113,265,364
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
ISO |
[delta-hexachlorocyclohexane co-treated with Lanthanum] promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]]; Lanthanum promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]] |
CTD |
PMID:9316872 |
|
NCBI chr10:27,090,913...27,179,786
Ensembl chr10:27,092,827...27,179,900
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Lanthanum binds to and results in increased expression of HSPA5 protein |
CTD |
PMID:18773883 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Igf2 |
insulin-like growth factor 2 |
multiple interactions |
ISO |
Lanthanum inhibits the reaction [IGF2 protein results in increased import of Calcium] |
CTD |
PMID:2442157 |
|
NCBI chr 1:215,828,102...215,839,081
Ensembl chr 1:215,828,102...215,846,911
|
|
G |
Ins2 |
insulin 2 |
decreases response to substance |
ISO |
Lanthanum results in decreased susceptibility to INS protein |
CTD |
PMID:22031853 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
Lanthanum results in decreased expression of JUN mRNA |
CTD |
PMID:21695898 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Lanthanum promotes the reaction [LEP protein results in increased transport of Calcium] |
CTD |
PMID:20107083 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
decreases activity |
ISO |
Lanthanum results in decreased activity of TRPC6 protein |
CTD |
PMID:11179201 |
|
NCBI chr 8:6,811,543...6,917,534
Ensembl chr 8:6,811,543...6,917,535
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
Lanthanum inhibits the reaction [TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Calcium]] |
CTD |
PMID:11988098 |
|
NCBI chr 1:234,478,908...234,631,264
Ensembl chr 1:234,479,289...234,596,971
|
|
G |
Trpv6 |
transient receptor potential cation channel, subfamily V, member 6 |
multiple interactions increases uptake |
ISO |
Lanthanum inhibits the reaction [TRPV6 protein results in increased uptake of Calcium] TRPV6 protein results in increased uptake of Lanthanum |
CTD |
PMID:21146870 |
|
NCBI chr 4:70,918,631...70,934,291
Ensembl chr 4:70,918,632...70,934,295
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
ISO |
Lanthanum results in increased expression of XBP1 mRNA alternative form |
CTD |
PMID:18773883 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
|
G |
Agl |
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of AGL mRNA motexafin gadolinium results in decreased expression of AGL mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:219,788,234...219,843,189
Ensembl chr 2:219,788,234...219,842,986
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of ALDH5A1 mRNA] motexafin gadolinium results in increased expression of ALDH5A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ALDH6A1 mRNA Zinc Acetate inhibits the reaction [motexafin gadolinium results in decreased expression of ALDH6A1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 6:108,146,552...108,167,185
Ensembl chr 6:108,146,582...108,167,185
|
|
G |
Arhgap17 |
Rho GTPase activating protein 17 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ARHGAP17 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ARHGAP17 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:193,239,036...193,328,425
Ensembl chr 1:193,239,040...193,328,371
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of ATF3 mRNA] motexafin gadolinium results in increased expression of ATF3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of ATM mRNA] motexafin gadolinium results in increased expression of ATM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ATR mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ATR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BACH1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BACH1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:27,364,913...27,398,713
Ensembl chr11:27,364,916...27,398,842 Ensembl chr11:27,364,916...27,398,842
|
|
G |
Bag3 |
BAG cochaperone 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of BAG3 mRNA] motexafin gadolinium results in increased expression of BAG3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein] |
CTD |
PMID:20530418 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of BIRC5 mRNA] motexafin gadolinium results in increased expression of BIRC5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bmt2 |
base methyltransferase of 25S rRNA 2 homolog |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BMT2 mRNA motexafin gadolinium results in increased expression of BMT2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:40,064,131...40,136,074
Ensembl chr 4:40,063,932...40,136,061
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BNIP3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BNIP3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BNIP3L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BNIP3L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
|
|
G |
Canx |
calnexin |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CANX mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CANX mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CASP3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CASP3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cbfb |
core-binding factor subunit beta |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CBFB mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CBFB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:37,127,508...37,171,075
Ensembl chr19:37,127,508...37,171,069
|
|
G |
Ccnj |
cyclin J |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CCNJ mRNA motexafin gadolinium results in decreased expression of CCNJ mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:259,926,537...259,944,275
Ensembl chr 1:260,093,641...260,111,254 Ensembl chr 1:260,093,641...260,111,254
|
|
G |
Cdc16 |
cell division cycle 16 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDC16 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDC16 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:81,493,355...81,516,493
Ensembl chr16:81,493,355...81,516,493
|
|
G |
Cdc25c |
cell division cycle 25C |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDC25C mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CDC25C mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
|
|
G |
Cdc27 |
cell division cycle 27 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDC27 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CDC27 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:92,551,754...92,602,214
Ensembl chr10:92,554,081...92,602,082
|
|
G |
Cdc5l |
cell division cycle 5-like |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDC5L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDC5L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:17,949,764...17,988,514
Ensembl chr 9:17,949,764...17,988,509
|
|
G |
Cdca2 |
cell division cycle associated 2 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDCA2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDCA2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:44,365,396...44,411,601
Ensembl chr15:44,365,405...44,411,004
|
|
G |
Cdk19 |
cyclin-dependent kinase 19 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of CDK19 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr20:45,458,499...45,598,799
Ensembl chr20:45,458,558...45,598,798
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of CDK2 mRNA] motexafin gadolinium results in increased expression of CDK2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA] |
CTD |
PMID:20530418 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDKN1B mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CDKN1B mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CTH mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CTH mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Cul3 |
cullin 3 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CUL3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CUL3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:86,044,485...86,129,066
Ensembl chr 9:86,044,485...86,129,329
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CYB5R1 mRNA motexafin gadolinium results in increased expression of CYB5R1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:51,229,697...51,236,447
Ensembl chr13:51,229,890...51,236,463
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
multiple interactions decreases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DAPK3 mRNA] motexafin gadolinium results in decreased expression of DAPK3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:11,392,436...11,400,855
Ensembl chr 7:11,392,437...11,400,805
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DDIT3 mRNA] motexafin gadolinium results in increased expression of DDIT3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DDIT4 mRNA motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of DDIT4 mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of DDIT4 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Dedd2 |
death effector domain containing 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DEDD2 mRNA] motexafin gadolinium results in increased expression of DEDD2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:82,073,024...82,089,028
Ensembl chr 1:82,072,544...82,088,275
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of DFFB mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of DFFB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:171,250,559...171,261,875
Ensembl chr 5:171,249,633...171,262,119
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of DHCR7 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:217,018,916...217,034,890
Ensembl chr 1:217,018,916...217,034,904
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in decreased expression of DNAJB1 mRNA] motexafin gadolinium results in increased expression of DNAJB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DNAJB4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of DNAJB4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:257,394,692...257,425,344
Ensembl chr 2:257,394,818...257,425,242
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DNAJB6 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of DNAJB6 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of DNAJC3 mRNA] motexafin gadolinium results in increased expression of DNAJC3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:104,186,918...104,226,236
Ensembl chr15:104,186,792...104,226,329
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F1 mRNA motexafin gadolinium results in increased expression of E2F1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
E2f3 |
E2F transcription factor 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of E2F3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:36,334,136...36,408,831
Ensembl chr17:36,334,147...36,408,831
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of EGLN1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of EGLN1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:57,660,194...57,701,158
Ensembl chr19:57,662,278...57,699,113
|
|
G |
Elp1 |
elongator acetyltransferase complex subunit 1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ELP1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ELP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:73,503,406...73,552,798
Ensembl chr 5:73,503,407...73,552,798
|
|
G |
Eno1 |
enolase 1 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of ENO1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
|
|
G |
Fadd |
Fas associated via death domain |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of FADD mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of FADD mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of FAIM mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of FAIM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:107,225,119...107,247,228
Ensembl chr 8:107,225,212...107,241,224 Ensembl chr 8:107,225,212...107,241,224
|
|
G |
Fam162a |
family with sequence similarity 162, member A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of FAM162A mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of FAM162A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:67,618,683...67,646,253
Ensembl chr11:67,618,625...67,646,253
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of FASN mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Foxo3 |
forkhead box O3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of FOXO3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of FOXO3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of GCLM mRNA motexafin gadolinium results in increased expression of GCLM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gls |
glutaminase |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of GLS mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GLS mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Gpr146 |
G protein-coupled receptor 146 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GPR146 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:17,343,396...17,358,631
Ensembl chr12:17,345,510...17,358,617
|
|
G |
Gpt2 |
glutamic--pyruvic transaminase 2 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GPT2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:22,599,003...22,633,529
Ensembl chr19:22,590,881...22,632,071
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA] |
CTD |
PMID:20530418 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of GSR mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of GSR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gtf3c2 |
general transcription factor IIIC subunit 2 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GTF3C2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:26,560,601...26,584,533
Ensembl chr 6:26,560,601...26,584,535
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HBP1 mRNA motexafin gadolinium results in increased expression of HBP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:51,231,479...51,257,699
Ensembl chr 6:51,231,480...51,257,625
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
[motexafin gadolinium co-treated with Zinc Acetate] results in increased expression of HIF1A protein motexafin gadolinium results in increased expression of HIF1A protein |
CTD |
PMID:16357179 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hilpda |
hypoxia inducible lipid droplet-associated |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HILPDA mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HILPDA mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:56,547,600...56,550,584
Ensembl chr 4:56,549,739...56,549,993
|
|
G |
Hipk1 |
homeodomain interacting protein kinase 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HIPK1 mRNA] motexafin gadolinium results in increased expression of HIPK1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:206,224,015...206,274,910
Ensembl chr 2:206,224,015...206,274,079
|
|
G |
Hltf |
helicase-like transcription factor |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of HLTF mRNA motexafin gadolinium results in decreased expression of HLTF mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:104,854,571...104,914,338
Ensembl chr 2:104,854,572...104,914,173
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[motexafin gadolinium co-treated with Zinc Acetate] results in increased expression of HMOX1 protein; motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HMOX1 mRNA] motexafin gadolinium results in increased expression of HMOX1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HRK mRNA motexafin gadolinium results in increased expression of HRK mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:44,008,879...44,029,211
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSP90AB1 mRNA motexafin gadolinium results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPA1A mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of HSPA1A mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPA1B mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of HSPA1B mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPA4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:38,601,624...38,642,397
Ensembl chr10:38,601,624...38,642,397
|
|
G |
Hspa4l |
heat shock protein family A (Hsp70) member 4 like |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPA4L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:127,625,737...127,682,864
Ensembl chr 2:127,625,683...127,677,503
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HSPB1 mRNA] motexafin gadolinium results in increased expression of HSPB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPD1 mRNA] motexafin gadolinium results in increased expression of HSPD1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPH1 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HSPH1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of ID2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of ID2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:44,360,077...44,361,908
Ensembl chr 6:44,348,501...44,363,915
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of IKBKE mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of IKBKE mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:48,031,325...48,056,394
Ensembl chr13:48,031,410...48,056,394
|
|
G |
Irf2bp2 |
interferon regulatory factor 2 binding protein 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of IRF2BP2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of IRF2BP2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:59,497,021...59,502,298
Ensembl chr19:59,499,876...59,502,161
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of JUND mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of JUND mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:20,485,028...20,486,707
Ensembl chr16:20,485,029...20,486,707
|
|
G |
Kdm3a |
lysine demethylase 3A |
increases expression |
ISO |
motexafin gadolinium results in increased expression of KDM3A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:99,503,160...99,547,315
Ensembl chr 4:99,503,176...99,546,905
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of MDM2 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MDM2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mob1a |
MOB kinase activator 1A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of MOB1A mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MOB1A mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 4:115,024,927...115,041,904
Ensembl chr 4:115,024,927...115,041,899
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
[Zinc co-treated with motexafin gadolinium] results in increased expression of MT1A mRNA |
CTD |
PMID:15867382 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of MT2A mRNA] motexafin gadolinium results in increased expression of MT2A mRNA |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of MYD88 mRNA motexafin gadolinium results in decreased expression of MYD88 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Nadk |
NAD kinase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of NADK mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of NADK mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:172,984,930...173,015,505
Ensembl chr 5:172,986,291...173,015,494
|
|
G |
Nf1 |
neurofibromin 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of NF1 mRNA motexafin gadolinium results in increased expression of NF1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:66,732,460...66,928,706
Ensembl chr10:66,690,133...66,928,903
|
|
G |
Nisch |
nischarin |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of NISCH mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:7,254,372...7,290,670
Ensembl chr16:7,254,974...7,290,561
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of NR1D2 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of NR1D2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr15:8,730,871...8,757,165
Ensembl chr15:8,730,871...8,757,165
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of P4HB mRNA] motexafin gadolinium results in increased expression of P4HB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:109,736,459...109,748,070
Ensembl chr10:109,736,458...109,747,987
|
|
G |
Pdcd11 |
programmed cell death 11 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PDCD11 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:266,866,931...266,908,042
Ensembl chr 1:266,866,931...266,908,042
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PDCD4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PDCD4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:274,616,625...274,648,204
Ensembl chr 1:274,625,224...274,648,204
|
|
G |
Pdcd5 |
programmed cell death 5 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of PDCD5 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of PDCD5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:91,173,473...91,178,801
Ensembl chr 1:91,173,473...91,178,801 Ensembl chr 1:91,173,473...91,178,801
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PFKFB3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PFKFB3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:70,632,778...70,713,736
Ensembl chr17:70,684,134...70,713,726
|
|
G |
Pfkfb4 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PFKFB4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PFKFB4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:117,733,347...117,776,525
Ensembl chr 8:117,737,117...117,775,386
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PGK1 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PGK1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr X:77,263,399...77,279,373
Ensembl chr X:77,263,359...77,279,367
|
|
G |
Phtf2 |
putative homeodomain transcription factor 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PHTF2 mRNA] motexafin gadolinium results in increased expression of PHTF2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:10,823,191...10,938,273
Ensembl chr 4:10,823,281...10,938,318
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PIAS1 mRNA] motexafin gadolinium results in increased expression of PIAS1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:67,771,720...67,869,015
Ensembl chr 8:67,771,720...67,869,019
|
|
G |
Pik3ip1 |
phosphoinositide-3-kinase interacting protein 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PIK3IP1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PIK3IP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:83,559,397...83,572,481
Ensembl chr14:83,560,541...83,572,473
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PMAIP1 mRNA motexafin gadolinium results in increased expression of PMAIP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PRKACB mRNA motexafin gadolinium results in increased expression of PRKACB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:252,602,197...252,691,886
Ensembl chr 2:252,605,307...252,691,886
|
|
G |
Prkcd |
protein kinase C, delta |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PRKCD mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
|
|
G |
Prkd2 |
protein kinase D2 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PRKD2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:78,767,911...78,796,223
Ensembl chr 1:78,767,911...78,796,231
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
increases expression |
ISO |
motexafin gadolinium results in increased expression of PRKDC mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:89,293,547...89,510,948
Ensembl chr11:89,293,696...89,510,871
|
|
G |
Ptrh2 |
peptidyl-tRNA hydrolase 2 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of PTRH2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of PTRH2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:74,002,151...74,012,182
Ensembl chr10:74,002,151...74,012,159
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of RB1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of RB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rcbtb2 |
RCC1 and BTB domain containing protein 2 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of RCBTB2 mRNA motexafin gadolinium results in decreased expression of RCBTB2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:55,029,388...55,074,728
Ensembl chr15:55,034,033...55,073,437
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of RELB mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of RELB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:80,517,081...80,545,019
Ensembl chr 1:80,517,411...80,544,825
|
|
G |
Rnf19b |
ring finger protein 19B |
increases expression |
ISO |
motexafin gadolinium results in increased expression of RNF19B mRNA |
CTD |
PMID:15867382 |
|
NCBI chr 5:147,246,032...147,270,892
Ensembl chr 5:147,246,037...147,270,957
|
|
G |
Selenow |
selenoprotein W |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SELENOW mRNA motexafin gadolinium results in increased expression of SELENOW mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:77,530,692...77,535,765
Ensembl chr 1:77,533,148...77,535,681 Ensembl chr 1:77,533,148...77,535,681
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions increases expression |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA; [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SESN2 mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA] motexafin gadolinium results in increased expression of SESN2 mRNA |
CTD |
PMID:16357179 PMID:20530418 |
|
NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC16A1 mRNA] motexafin gadolinium results in increased expression of SLC16A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:207,108,552...207,129,352
Ensembl chr 2:207,108,552...207,128,554
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC16A6 mRNA motexafin gadolinium results in increased expression of SLC16A6 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:97,733,701...97,758,723
Ensembl chr10:97,735,548...97,756,521
|
|
G |
Slc1a4 |
solute carrier family 1 member 4 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC1A4 mRNA] motexafin gadolinium results in increased expression of SLC1A4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:104,582,884...104,612,417
Ensembl chr14:104,581,190...104,612,597
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
multiple interactions increases expression |
ISO |
[Zinc co-treated with motexafin gadolinium] results in increased expression of SLC30A1 mRNA; motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC30A1 mRNA]; Zinc Acetate affects the reaction [motexafin gadolinium results in increased expression of SLC30A1 mRNA] |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr13:110,677,810...110,681,683
Ensembl chr13:110,677,810...110,681,683
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC38A2 mRNA]; Zinc Acetate affects the reaction [motexafin gadolinium results in increased expression of SLC38A2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 7:138,088,654...138,100,869
Ensembl chr 7:138,088,649...138,100,841
|
|
G |
Slc39a10 |
solute carrier family 39 member 10 |
multiple interactions affects expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC39A10 mRNA motexafin gadolinium affects the expression of SLC39A10 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:59,947,562...60,070,549
Ensembl chr 9:60,021,534...60,070,552
|
|
G |
Slc39a14 |
solute carrier family 39 member 14 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC39A14 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC39A14 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:51,982,872...52,029,841
Ensembl chr15:51,982,982...52,029,816
|
|
G |
Slc39a9 |
solute carrier family 39, member 9 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC39A9 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC39A9 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:104,291,001...104,326,553
Ensembl chr 6:104,291,071...104,329,872
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC3A2 mRNA motexafin gadolinium results in increased expression of SLC3A2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:224,906,566...224,921,029
Ensembl chr 1:224,906,554...224,921,092
|
|
G |
Slc43a1 |
solute carrier family 43 member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC43A1 mRNA motexafin gadolinium results in increased expression of SLC43A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:72,238,796...72,265,023
Ensembl chr 3:72,238,981...72,264,466
|
|
G |
Slc7a1 |
solute carrier family 7 member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC7A1 mRNA motexafin gadolinium results in increased expression of SLC7A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:8,032,775...8,108,972
Ensembl chr12:8,032,809...8,108,972
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC7A11 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC7A11 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
|
|
G |
Smarca4 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of SMARCA4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SMARCA4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:22,648,323...22,739,468
Ensembl chr 8:22,648,323...22,739,468
|
|
G |
Smarca5 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of SMARCA5 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SMARCA5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:30,936,703...30,969,454
Ensembl chr19:30,936,703...30,969,454
|
|
G |
Tagap |
T-cell activation RhoGTPase activating protein |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TAGAP mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TAGAP mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:47,493,990...47,503,492
Ensembl chr 1:47,493,994...47,502,952
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of TFRC mRNA] motexafin gadolinium results in increased expression of TFRC mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tnfaip8 |
TNF alpha induced protein 8 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of TNFAIP8 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TNFAIP8 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:44,664,310...44,779,914
Ensembl chr18:44,716,226...44,779,914
|
|
G |
Tnfrsf17 |
TNF receptor superfamily member 17 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TNFRSF17 mRNA motexafin gadolinium results in decreased expression of TNFRSF17 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:4,252,097...4,258,335
Ensembl chr10:4,251,941...4,257,868
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TNFRSF1A mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of TNFSF8 mRNA] motexafin gadolinium results in increased expression of TNFSF8 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:79,664,779...79,691,547
Ensembl chr 5:79,664,765...79,691,258
|
|
G |
Tnip2 |
TNFAIP3 interacting protein 2 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of TNIP2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:81,487,934...81,505,889
Ensembl chr14:81,488,008...81,504,686
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein; Acetylcysteine inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] |
CTD |
PMID:20530418 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TRIB3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TRIB3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TXNRD1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TXNRD1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of VEGFA mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of VEGFA mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vhl |
von Hippel-Lindau tumor suppressor |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of VHL mRNA] motexafin gadolinium results in increased expression of VHL mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:145,580,869...145,587,835
Ensembl chr 4:145,580,799...145,587,845
|
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Neodymium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:82,129,071...82,197,828
Ensembl chr10:82,129,506...82,197,848
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases phosphorylation increases expression |
ISO |
Neodymium results in decreased phosphorylation of HSPB1 protein Neodymium results in increased expression of HSPB1 mRNA; Neodymium results in increased expression of HSPB1 protein |
CTD |
PMID:20332019 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Psmb2 |
proteasome 20S subunit beta 2 |
decreases expression |
ISO |
Neodymium results in decreased expression of PSMB2 protein |
CTD |
PMID:20332019 |
|
NCBI chr 5:144,702,004...144,734,220
Ensembl chr 5:144,701,949...144,734,257
|
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
increases mutagenesis |
EXP |
Plutonium results in increased mutagenesis of HRAS gene |
CTD |
PMID:9255578 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
|
G |
Aadat |
aminoadipate aminotransferase |
affects expression |
ISO |
Uranium affects the expression of AADAT mRNA |
CTD |
PMID:15672453 |
|
NCBI chr16:32,832,001...32,868,680
Ensembl chr16:32,832,061...32,868,702
|
|
G |
Aanat |
aralkylamine N-acetyltransferase |
affects expression |
ISO |
Uranium affects the expression of AANAT mRNA |
CTD |
PMID:15672453 |
|
NCBI chr10:105,568,091...105,572,407
Ensembl chr10:105,568,091...105,572,403
|
|
G |
Aasdhppt |
aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase |
affects expression |
ISO |
Uranium affects the expression of AASDHPPT mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 8:1,432,757...1,450,175
Ensembl chr 8:1,439,340...1,450,138
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
[Acetaminophen co-treated with Uranium analog] results in increased expression of ABCC2 mRNA; Uranium analog promotes the reaction [Acetaminophen results in increased expression of ABCC2 mRNA] |
CTD |
PMID:17126469 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
affects expression |
ISO |
Uranium affects the expression of ABCC8 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 1:102,110,708...102,191,287
Ensembl chr 1:102,110,708...102,191,287
|
|
G |
Abcf2 |
ATP binding cassette subfamily F member 2 |
affects expression |
ISO |
Uranium affects the expression of ABCF2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 4:7,122,850...7,135,607
Ensembl chr 4:7,122,890...7,135,669
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
affects expression |
ISO |
Uranium affects the expression of ACAT2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 1:47,972,399...47,992,654
Ensembl chr 1:47,972,399...47,992,653
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
increases expression increases secretion multiple interactions |
EXP |
Uranium results in increased expression of ACP5 protein Uranium results in increased secretion of ACP5 protein GHRL protein inhibits the reaction [Uranium results in increased secretion of ACP5 protein] |
CTD |
PMID:16436523 PMID:29477364 |
|
NCBI chr 8:23,142,733...23,149,067
Ensembl chr 8:23,142,734...23,148,396
|
|
G |
Actb |
actin, beta |
affects expression |
ISO |
Uranium affects the expression of ACTB mRNA; Uranium affects the expression of ACTB protein |
CTD |
PMID:15672453 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Actr2 |
actin related protein 2 |
affects expression |
ISO |
Uranium affects the expression of ACTR2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr14:104,338,486...104,375,840
Ensembl chr14:104,340,434...104,375,649
|
|
G |
Adar |
adenosine deaminase, RNA-specific |
affects expression |
ISO |
Uranium affects the expression of ADAR mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 2:189,045,551...189,085,448
Ensembl chr 2:189,062,443...189,083,236
|
|
G |
Adnp |
activity-dependent neuroprotector homeobox |
affects expression |
ISO |
Uranium affects the expression of ADNP mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 3:164,937,188...164,964,819
Ensembl chr 3:164,937,198...164,964,702
|
|
G |
Akap1 |
A-kinase anchoring protein 1 |
affects expression |
ISO |
Uranium affects the expression of AKAP1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr10:76,151,013...76,183,987
Ensembl chr10:76,151,038...76,166,276
|
|
G |
Akirin1 |
akirin 1 |
increases expression |
ISO |
Uranium results in increased expression of AKIRIN1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 5:141,415,226...141,430,627
Ensembl chr 5:141,415,075...141,430,659
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
affects expression |
ISO |
Uranium affects the expression of AKR1C3 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions decreases secretion |
EXP |
GHRL protein inhibits the reaction [Uranium results in decreased secretion of ALPL protein] |
CTD |
PMID:29477364 |
|
NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
|
|
G |
Apbb1 |
amyloid beta precursor protein binding family B member 1 |
affects expression |
ISO |
Uranium affects the expression of APBB1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 1:170,387,625...170,411,263
Ensembl chr 1:170,387,609...170,404,056
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
affects expression |
ISO |
Uranium affects the expression of APC mRNA |
CTD |
PMID:15672453 |
|
NCBI chr18:27,011,710...27,106,323
Ensembl chr18:27,047,382...27,105,531
|
|
G |
App |
amyloid beta precursor protein |
affects expression |
ISO |
Uranium affects the expression of APP mRNA |
CTD |
PMID:15672453 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
affects expression |
ISO |
Uranium affects the expression of APPL1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr16:2,560,103...2,602,035
Ensembl chr16:2,563,520...2,602,103
|
|
G |
Ar |
androgen receptor |
decreases expression |
EXP |
Uranium analog results in decreased expression of AR mRNA |
CTD |
PMID:27544493 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Armc9 |
armadillo repeat containing 9 |
increases expression |
ISO |
Uranium results in increased expression of ARMC9 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 9:93,172,718...93,299,119
Ensembl chr 9:93,172,673...93,296,750
|
|
G |
Asap2 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 |
affects expression |
ISO |
Uranium affects the expression of ASAP2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 6:43,231,178...43,348,606
Ensembl chr 6:43,234,526...43,343,551
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
increases expression |
EXP |
Uranium results in increased expression of ASCL1 mRNA |
CTD |
PMID:27639536 |
|
NCBI chr 7:28,038,662...28,040,504
Ensembl chr 7:28,038,662...28,040,510
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
affects expression |
ISO |
Uranium affects the expression of ATP6V1A mRNA |
CTD |
PMID:15672453 |
|
NCBI chr11:61,531,386...61,584,634
Ensembl chr11:61,531,416...61,584,634
|
|
G |
Atp9b |
ATPase phospholipid transporting 9B (putative) |
affects expression |
ISO |
Uranium affects the expression of ATP9B mRNA |
CTD |
PMID:15672453 |
|
NCBI chr18:77,343,551...77,535,608
Ensembl chr18:77,343,551...77,535,593
|
|
G |
Atxn10 |
ataxin 10 |
affects expression |
ISO |
Uranium affects the expression of ATXN10 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 7:126,228,416...126,351,728
Ensembl chr 7:126,228,295...126,351,634
|
|
G |
B2m |
beta-2 microglobulin |
affects expression |
ISO |
Uranium affects the expression of B2M mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
|
|
G |
Baalc |
BAALC binder of MAP3K1 and KLF4 |
affects expression |
ISO |
Uranium affects the expression of BAALC mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 7:77,761,056...77,836,534
Ensembl chr 7:77,763,512...77,837,453
|
|
G |
Bace1 |
beta-secretase 1 |
affects expression |
ISO |
Uranium affects the expression of BACE mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 8:50,140,092...50,162,388
Ensembl chr 8:50,139,997...50,162,361
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression decreases secretion multiple interactions |
EXP ISO |
Uranium results in increased expression of BGLAP protein Uranium results in increased expression of BGLAP mRNA Uranium results in decreased secretion of BGLAP protein GHRL protein inhibits the reaction [Uranium results in decreased secretion of BGLAP protein] |
CTD |
PMID:16436523 PMID:29477364 PMID:31120128 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Bgn |
biglycan |
affects expression |
ISO |
Uranium affects the expression of BGN mRNA |
CTD |
PMID:15672453 |
|
NCBI chr X:157,319,042...157,331,204
Ensembl chr X:157,319,046...157,331,204
|
|
G |
Btf3 |
basic transcription factor 3 |
affects expression |
ISO |
Uranium affects the expression of BTF3 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 2:28,417,316...28,424,436
Ensembl chr 2:28,417,579...28,423,762
|
|
G |
Calb1 |
calbindin 1 |
decreases expression |
EXP |
Uranium results in decreased expression of CALB1 mRNA |
CTD |
PMID:17118558 |
|
NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773
|
|
G |
|